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INTRODUCTION 
 
 
 
 
 
 INTRODUCTION 
 
Hypothyroidism is one of the most common endocrine disorders, affecting over one 
percent of the general population and about 5 percent of individuals over age of 60 
years [1, 2]. It is a syndrome characterised by the clinical and biochemical 
manifestation of thyroid hormone deficiency in the target tissue [3]. Iodine 
deficiency remains the most common cause of hypothyroidism worldwide. In areas 
of iodine sufficiency, autoimmune disease (Hashimotos thyroiditis) and iatrogenic 
causes (treatment for hypothyroidism) are most common [4].  
Thyroid hormone is essential for early brain development and play a key role in 
later brain functioning. It is involved in fundamental neurologic processes such as 
neurogenesis, axon and dendritic formation, neuronal migration, and 
synaptogenesis, with the timing of need for thyroid hormone varying among 
different brain structures. Structures showing the greatest need for thyroid hormone 
are the thalamus, cerebellum, caudate nucleus, hippocampus, cerebral cortex. In 
addition, thyroid hormone is involved in cochlear and retinal development. Thyroid 
hormone act by regulating specific brain genes and this thyroid specific gene 
regulation is accomplished via a set of distinct thyroid hormone receptors; the 
receptor distribution varies ontologically and regionally, with some brain structures 
showing a great need for thyroid hormone than others. This finding is significant for 
humans, in whom impairment from early thyroid hormone loss is more likely to 
result in specific than global deficits; the exact nature will depend on the precise 
timing of thyroid hormone insufficiency [5]. 
Thyroid hormone deficiency is associated with peripheral and central nervous 
system dysfunction. The Central nervous system manifestations include slowing of 
all intellectual functions, lethargy, somnolence, loss of initiative, memory defects, 
depression and rarely convulsions and coma. [6] 
 The metabolic abnormalities decreased cerebral blood flow or abnormal 
depositions of mucopolysaccharride that usually accompany hypothyroidism are 
believed to cause these symptoms [7].These CNS manifestations are largely 
reversible with treatment [8]. 
 Involvement of central nervous system in overt hypothyroidism has previously 
been shown by (Ladenson et al, Kedhr et al)  on the basis of visual evoked potential 
in adult patients and of BAEPS (A.R.D.thornton, S.J.Jarvis) and SSEPS in infants 
and adults (Bongers –Schokking et al, Ozkardes et al) [7, 9-12]. 
In our country, a large number of patients are suffering from thyroid deficiency 
which varies from mild to severe form. As most of the patients are illiterate and of 
low socio economic status, they were not aware about consequences as well as the 
complication of delayed or irregular treatment. Evoked potentials are particularly 
suited for a non invasive evaluation of a number of afferent pathways in the nervous 
system [11]. 
Hence the electrophysiological study was done in hypothyroid patients, even in the 
asymptomatic ones, early in the course of disease in order to detect the nervous 
system involvement. 
 
 
 
 
 
  
  
 
 
 
 
 
AIM & OBJECTIVES  
 
 
 
 
 
 
 
 AIM AND OBJECTIVES 
 
 This study was undertaken to compare electrophysiological parameters 
between hypothyroid patients and control.  
 
 To evaluate functional changes in nervous system in hypothyroidism by 
different electrophysiological parameters like visual evoked potential, Brain 
stem auditory evoked potential, Somatosensory evoked potential. 
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 REVIEW & LITERATURE 
 
THYROID GLAND: 
The thyroid gland was first described by Galen [130-210 AD] in his work “De 
voce”. The gland was named thyroid by Thomas Whorton (1614-1673) because of 
its proximity to the thyroid cartilage. Despite its name (thyreos in Greek means 
“shield”, and “schilddruse” in German means “shield gland”). The active principle 
of the thyroid extract was isolated by Kendall on Christmas day 1914 and named 
thyroxine [13]. 
EPIDEMIOLOGY:  
Thyroid disease is common, particularly in women, with prevalence in community 
of 3-5% [14]. Primary hypothyroidism is a common disease worldwide, especially in 
iodine deficient area. It accounts for approximately 99% of case, with less than 1% 
being due to Thyrotropin (TSH) deficiency known as central or secondary 
hypothyroidism [15]. Hashimoto’s thyroiditis / chronic lymphocytic thyroiditis is the 
commonest cause of goitrous hypothyroidism in iodine sufficient parts of the world. 
It is predominantly a disease of women, with a female to male ratio of 5:1 [16]. The 
mean annual incidence rate of autoimmune hypothyroidism is up to 4 per 1000 
women and 1per 1000 men [4]. 
 
 FUNCTIONAL ANATOMY OF THYROID GLAND: 
The thyroid is one of the largest endocrine organs, weighing approximately 
20gms.The thyroid gland is made up of two lobes of endocrine tissue joined in the 
middle by a narrow band of tissue, the isthmus, and giving it a bow tie shaped 
appearance and is located on either side of trachea just below the larynx. Each lobe 
of thyroid gland is divided into various lobules by fibrous tissue septa. Each lobule 
is made up of an aggregation of several follicles. Follicle is the functional unit of 
thyroid gland.  
 Thyroglobulin is considered as the chief substances of the colloid, which is found 
to be a large complex molecule. Thyroid hormones are incorporated within them in 
various stages. Thyroxine (T4) and triiodothyronine (T3) are derived from the amino 
acid tyrosine, which are produced by follicular cells. 
SYNTHESIS AND STORAGE OF THYROID HORMONE: 
Tyrosine and iodine are the basic ingredients for thyroid hormone synthesis. Both of 
which must be taken up from the blood by the follicular cells. All the steps of 
thyroid hormone synthesis occur on the large thyroglobulin molecule, which 
subsequently store the hormones. The steps involved in the synthesis of thyroid 
hormones are: 
a.) Iodine Trapping: The first step in the synthesis of thyroid hormones is uptake 
of iodide by thyroid gland which occurs against the electrochemical gradients by a 
sodium iodide co transport /symport system or iodine pump that is located in the 
outer membranes of the follicular cells. Almost of all of the iodine in the body is 
moved against its concentration gradient to become trapped in the thyroid for the 
purpose of thyroid synthesis. 
 
Fig: 1 steps in synthesis and release of thyroid hormones 
b.) Synthesis and secretion of thyroglobulin: Thyroglobulin is a large 
glycoprotein that is synthesized on the rough endoplasmic reticulum of thyroid 
follicular cells as peptide unit of molecular weight 3, 30,000. These units combine 
into a dimer, after which carbohydrate moieties are added as the molecule moves to 
the Golgi apparatus. The completed glycoprotein is contained in small vesicles, 
which move to the apical plasma membrane and release into the lumen of follicle. 
Each molecule of thyroglobulin contains about 123 tyrosine residues which can 
serve as substrate for the formation of thyroid hormones. 
c.) Oxidation of iodide: Once within the gland, iodide rapidly moves to the apical 
surface of the follicular cells. From these, it is transported into the lumen of the 
follicles by a sodium independent iodide/chloride transporter called Pendrin. The 
iodide is then immediately oxidised to iodine by the enzyme peroxidase present 
near the apical border of the follicular cells. The immediate oxidant for this reaction 
is hydrogen peroxidase which is supplied by an NADPH dependent system. 
d.) Organification of thyroglobulin: Within the colloid, iodine is quickly attached 
to a tyrosine within the thyroglobulin molecule and this refers to iodination of 
tyrosine residue. Tyrosine of thyroglobulin is first iodinated at position 3 to form 
monoiodotyrosine (MIT) and then at position 5 to form diiodotyrosine (i.e.) 
attachment of one iodine to tyrosine yields monoiodotyrosine, attachment of two 
iodines to tyrosine yields diiodotyrosine respectively. This reaction occurs at the 
apical membrane of the cell as soon as thyroglobulin molecule is released by the 
secretory granules by exocytosis and requires thyroid peroxidase. 
e.) Coupling reaction: The process of iodination of tyrosine residues is followed 
by coupling reaction, which lasts for few minutes to hour. Coupling of two DITs 
(each bearing two iodine atoms) yields tetraiodothyronine (T4) the iodine form of 
thyroid hormone. Coupling of one MIT (with one iodine) and one DIT (with two 
iodines) yields triiodothyronine (T3).Coupling does not occurs between two MIT 
molecules. The enzyme peroxidase is required during coupling. 
f.) Storage: Once thyroglobulin has been iodinated is stored in the lumen of the 
follicle as colloid until they are split off and secreted. It is estimated that the stored 
thyroid hormones can meet the body requirements for 1-3 months. 
SECRETION OF THYROID HORMONE: 
Once thyroglobulin has been iodinated, it is stored in the lumen of the follicle as 
colloid. Release of Thyroxine and Triiodothyronine into the blood stream requires 
binding of thyroglobulin to the receptor megalin, followed by endocytosis and 
lysosomal degradation of thyroglobulin. Enzymatically released Thyroxine and 
Triiodothyronine then leaves the basal side of the cell and enters the blood. The 
MIT and DIT are rapidly deiodinated within the follicular cells by the enzyme 
deiodinase. In this way iodide is retrieved for recycling along with the tyrosine into 
T4 and T3 synthesis [17]. 
 
 
 
 
 
 CHARACTERISTIC OF CIRCULATING TRIIODOTHYRONINE (T3) &  
THYROXINE (T4): 
Hormone property T3 T4 
 
Concentration of total hormone 0.14µg/dl 8µg/dl 
Fraction of total hormone in the 
free 
Form 
0.3% 0.02% 
Free (unbound form) 6×10 -12 M 21×10 -12 M 
Fraction directly from the 
thyroid 
20 % 100% 
Serum half life 0.75 days 7 days 
Intra cellular hormone fraction 70% 20% 
Relative metabolic potency 1 0.3 
Production rate, including 
Peripheral conversion 
32µg/d 90µg/d 
Receptor binding 10 -11 M 10-10 M 
 
 
 
 REGULATION OF THYROID HORMONE FUNCTION & SYNTHESIS: 
The large intra-glandular store of hormone buffers the effect of acute increase or 
decreases in hormone synthesis. Autoregulatory mechanism within the gland in turn 
tend to maintain the constancy of the thyroid hormone pool. Finally the classic 
feedback mechanism sense variation in the availability of thyroid hormones and 
their metabolic impact at the periphery. 
HYPOTHALAMIC-PITUITARY-THYROID AXIS SYSTEM: 
The Hypothalamic-pituitary-thyroid axis is a classic example of an endocrine 
feedback loop. Hypothalamic thyrotropin releasing hormone (TRH) stimulates 
production of thyroid stimulating hormone (TSH) by pituitary gland, which in turn, 
stimulates thyroid hormone synthesis and secretion [4]. 
PHYSIOLOGICAL ACTIONS OF THYROID HORMONES: 
Thyroid hormone is the primary determinant of the body’s overall metabolic rate 
and is also important for bodily growth and normal development and function of the 
nervous system. 
EFFECT ON BASAL METABOLIC RATE: 
Thyroid hormone in general increases the body’s overall basal metabolic activities. 
They are calorigenic and hence, increase oxygen consumption and heat production 
[18]
. The basal metabolic rate can increase by 60 percent to 100 percent above 
normal when large amount of T4 are present [16].   
 CALORIGENIC EFFECT: 
Increased metabolic activity results in increased heat production. Thermogenesis 
must also increase concomitantly with oxygen use [19]. 
Thyroid hormones increase membrane Na+ k+ adenosine triphosphatase (ATPase) 
concentration and activity and increase membrane Na+ and K+ permeability. As 
much as 15% to 40% of the basal energy used in the cell is applied to maintaining 
this electrochemical gradient. Thyroid hormone increases the activity of Na+ K+ 
ATPase and hence, increases energy expenditure in resting cells. It increases energy 
expenditure by increasing futile cycling because they frequently stimulate both 
anabolic and catabolic enzymes of the same pathway [18]. 
EFFECT ON NERVOUS SYSTEM: 
Thyroid hormone regulates the timing and pace of development of the central 
nervous system [19]. They regulate neuronal proliferation, and differentiation, 
myelinogenesis, neuronal outgrowth, and synapse formation [18]. Thyroid hormone 
acts by regulating specific brain gene, which underlie the basic processes of brain 
development. Thyroid specific gene regulation is accomplished via a set of distinct 
thyroid hormone receptors, which along with specific coactivators and corepressors 
activate or deactivate particular brain genes. It also plays an important role in 
neurotransmission [5]. 
During early life, thyroid hormone controls production of neurotransmitters, 
whereas in later life, thyroid hormone regulates catecholamine production and 
responsiveness. In addition, thyroid hormone a.) Activates neurones via astrocytes, 
b.) Affects synaptic transmission between neurons through release of glutamate, c.) 
Up regulates sodium – dependent neurotransmitter transporter gene and other genes 
involved in neurotransmitter function, and d.) Control GABA release and reuptake, 
as well as GABA receptor function. Furthermore, thyroid hormone effects on 
neurotransmitter function are different in the developing brain than in adult brain. 
Because these actions have functional implications for humans, they underscore the 
need to maintain proper levels of thyroid hormone beyond the period of early brain 
growth. [4] 
Thyroid hormone also enhances alertness, wakefulness, and learning capacity, 
auditory sense, and awareness of hunger, memory, and responsiveness to various 
stimuli. Furthermore, the speed and amplitude of peripheral nerve reflexes are 
increased by thyroid hormone [19]. 
HYPOTHYROIDISM:  
Reduced production of thyroid hormone by the thyroid gland results in the clinical 
state termed hypothyroidism. It may be primary or secondary. 
Hypothyroidism as a clinical syndrome was described in 1874 by Gull under the 
name of myxedema in view of the swollen skin (edema) and its excessive content of 
mucin [3]. 
 
PRIMARY HYPOTHYROIDISM: 
Primary hypothyroidism refers to thyroid hormone deficiency caused by intrinsic 
deficiency (i.e. permanent loss or destruction of the thyroid, through processes such 
as autoimmune destruction or irradiation injury) of the thyroid gland that affects the 
synthesis and secretion of T4 and T3 [20].  
SECONDARY HYPOTHYROIDISM: 
Secondary hypothyroidism refers to insufficient stimulation of a thyroid gland, as 
the result of hypothalamic or pituitary disease or defects in the TSH molecule [15]. 
ETIOLOGY: 
The causes of hypothyroidism vary, depending on whether the disease is primary or 
secondary. 
CAUSES OF HYPOTHYROIDISM 
Primary hypothyroidism: 
Autoimmune Hypothyroidism: Hashimotos thyroiditis 
        Atrophic thyroiditis. 
Iatrogenic        : 131 I treatment, Subtotal or 
Total thyroidectomy, Therapeutic irradiation   for 
Non thyroidal malignancy. 
Congenital Hypothyroidism    :      Thyroid agenesis or dysplasia, 
       Dyshormonogenesis, 
       TSH receptor defects, 
       Iodine deficiency, 
                                    Idiopathic TSH unresponsiveness. 
Drugs       :  Iodide, Lithium, antithyroid dugs,  
 Sulfonamides, and ethionamide, 
 Cytokines(interferon-α,interleukin-2)    
 aminoglutethimide. 
Thyroid Infiltration    :  Amyloidosis, sarcoidosis,  
 Hemochromatosis, scleroderma, cystinosis,  
 Riedels Struma, over expression of type III  
 Deiodinase in infantile haemangioma. 
Secondary Hyperthyroidism: 
Acquired: 
Hypopitutarism  :  Tumors, Sheehan’s syndrome  
 Pituitary Surgery, 
      Irradiation,  
 Infiltrative disorders, 
     Trauma, 
Genetic forms of combined pituitary                      
hormone deficiencies. 
 
Hypothalamic Diseases : Tumours, 
     Trauma, 
     Infiltrative Disorders, 
     Idiopathic. 
 
Bexarotene treatment 
(Retinoid X receptor agonist). 
Congenital: 
TSH deficiency or structural abnormality 
TSH receptor defect 
Transient Hypothyroidism: 
 
- Subacute thyroiditis, 
- Silent thyroiditis, including postpartum thyroiditis, 
- After 131I treatment or subtotal thyroidectomy for Graves disease. 
- Withdrawal of thyroxine treatment in individuals with an infarct thyroid. 
 
PATHOGENESIS: 
Clinical hypothyroidism shows deficiency of thyroid hormones and their action at 
the target tissue level.  Binding of T3 to the receptor complex which in turn bind to 
thyroid receptor elements are located on certain genes over the regulatory regions. 
Based on the variation it shows response to thyroid hormones. The effect of 
hypothyroidism can be best studied on the basis of specific deficiency of molecular 
action [21]. 
Autoimmune thyroiditis is characterised by thyroid cell apoptosis leading to 
follicular destruction rather than thyroid stimulation and thyroid cell hyperplasia. 
Although both auto antibodies to thyroid peroxidase and thyroglobulin may be 
complement-fixing and cytotoxic, the thyroid gland is infiltrated by both B cells and 
T cells; the latter are armed with Fas ligand and capable of destroying thyroid cells 
expressing Fas via apoptosis [15]. 
CLINICAL MAINFESTATIONS OF HYPOTHYROIDISM: 
Hypothyroidism can affect all organ systems of the body, and these manifestations 
are largely depends on the degree of hormone deficiency. 
 
 
Symptoms:  
 Fatigue 
Lethargy 
Sleepiness 
Depression 
Cold intolerance 
Hoarseness 
Dryness of skin 
Decreased perspiration 
Weight gain 
Decreased appetite 
Constipation 
Menstrual irregularities 
Joint pain 
Paresthesia 
Signs: 
Slow speech                                                                                            
Slow movements 
Bradycardia 
Non pitting edema  
Hyporeflexia 
Delayed relaxation of reflexes 
Symptoms and signs associated with specific causes of hypothyroidism: 
Diffuse or nodular goiter 
Symptoms and signs of pituitary or hypothalamic tumor 
 Visual impairment, Headache [8] 
EFFECTS OF HYPOTHYROIDISM IN BRAIN: 
 In hypothyroidism, Neurological complications are more common and all levels of 
the nervous system may be involved. Hormonal alterations and immune 
mechanisms are the possible explanations for the neurological complications in 
hypothyroidism [22]. 
The neurologic manifestations of acquired hypothyroidism in chidren and adults are 
varied [8] and include mental changes, seizures, dementia, cerebellar ataxia, cranial 
nerve disorders, sleep apnea and coma. 
MENTAL DYSFUNCTION: 
Mental and psychological dysfunction is relatively common in untreated 
hypothyroidism. All intellectual functions, including speech, are slowed in thyroid 
hormone deficiency. Loss of initiative is present, slow wittedness and memory 
defects are also common, lethargy and somnolence are prominent, and dementia in 
elderly patients may be mistaken for senile dementia. Headaches are frequent. 
Psychiatric disorders are common and are usually of the paranoid or depressive type 
and may induce agitation (myxedema madness) [15]. 
 SEZIURE: 
 About 20 percent of patients with untreated hypothyroidism will develop seizures 
or syncopal episodes. Cerebral hypoxia due to circulatory alterations may 
predispose to confusional attacks and syncope. Drop attacks also occur as a 
complication of hypothyroidism that resolves with hormone replacement therapy 
[22]
. 
CEREBELLAR ATAXIA: 
Acquired cerebellar ataxia has been described in patients with hypothyroidism. 
Unsteadiness of gait may be found in the earliest clinical descriptions of 
hypothyroidism. Some patients describe clumsiness or unsteadiness of gait, but they 
have no nystagmus or other signs of cerebellar dysfunction. 
The rapid resolution of the ataxia with hormone replacement therapy in most 
patients suggests that the problem may be caused by a reversible metabolic factor 
[22]
. 
 
 
CRANIAL NERVE DISORDERS: 
Hearing loss: Deafness is a very characteristic and troublesome symptom in 
hypothyroidism [23]. About 25% of hypothyroid patients have substantial hearing 
loss. Both nerve and conduction deafness and combination of the two have been 
reported. 
Two-thirds of patients complain of dizziness, vertigo, or tinnitus occasionally, these 
problems again suggest damage to the cochlear nerve or labyrinth, or possibly to the 
cerebellum. Whatever type of deafness is present, there is marked improvement 
after thyroid hormone therapy [23]. 
Endemic cretinism is a congenital type of thyroid deficiency in humans. It has been 
associated with deformities of the malleus and incus, incomplete ossification of the 
stapes, distortions of the round and oval windows, poorly developed mastoid 
processes, thickened middle ear mucosa, and hyperostosis of the promontory, and 
even with occasional closure of the round window. 
Acquired hypothyroidism may follow drug treatment, surgery, or irradiation. It may 
also result from infections or dietary lack of iodine. 25 to 50% of these patients 
develop hearing loss that is occasionally reversible with thyroid hormone treatment. 
The level of hearing loss correlates somewhat with the severity of the thyroid 
hormone deficiency [24]. 
Visual deficit: In longstanding primary hypothyroidism, hyperplasia of the 
thyrotrope may cause pituitary gland enlargement. Pressure effect of enlarged 
pituitary on the optic chiasma results in subtle visual field defects in more number 
of patients with primary hypothyroidism [8]. Visual evoked potentials may be 
delayed as a consequence of abnormal cerebral cortical metabolism [23]. Thyroid 
hormone replacement therapy may lead to a reduction in pituitary size and an 
improvement in vision. 
  
DISORDERS OF SLEEP: 
 Disturbances of sleep are common in patients with hypothyroidism. Many of the 
hypothyroid patients have evidences of upper airway obstruction resulting from 
deposition of mucopolysaccharides and extravasation of protein into the tissues of 
the tongue and nasopharynx, as well as hypertrophy of the genioglossus and leading 
obstructive sleep apnea. In other patients, the sleep apnea seems to be central in 
origin. Disturbance in serotonin neurotransmission may be the mechanism involved 
in central apnea of hypothyroidism [22]. 
ENCEPHALOPATHY AND COMA: 
Occasionally, a life-threatening encephalopathy known as myxedema coma may 
result from a variety of precipitating factors causing decompensation of the 
physiological adaptations to hypothyroid state [22]. 
 Clinical features are universally present in myxedema coma are defective 
temperature control, depression of level of consciousness and a precipitating illness 
or event. The pathophysiology of myxedema coma involves three major aspects: a) 
carbon dioxide retention and hypoxia, b) fluid and electrolyte imbalance c) 
hypothermia. [16] 
HASHIMOTO’S ENCEPHALOPATHY: 
Hashimoto’s encephalopathy is a term that has been applied to patients with chronic 
autoimmune thyroiditis who have confusion, delirium, dementia, tremor, 
myoclonus, ataxia, focal or generalized seizures, and occasionally stroke-like 
episodes. There is a preponderance of female patients. Nearly all patients have had 
high serum concentrations of antithyroid peroxidase or other antithyroid antibodies. 
The encephalopathy usually well responds to gulcocorticoids [8]. 
  
PERIPHERAL NEUROPATHY IN HYPOTHYROIDISM: 
Neurologic complications, including polyneuropathy, are well-known finding in 
overt hypothyroidism, with a prevalence ranging from 42% to 72% [25]. Peripheral 
neuropathy may be a manifestation of hypothyroidism which usually develops 
insidiously over a long period of time due to irregular intake of drugs or lack of 
thyroid hormone replacement.  Both entrapment mononeuropathies and diffuse 
neuropathy are the complication of hypothyroidism [22]. 
 
ENTRAPMENT NEUROPATHY: 
Entrapment neuropathy, most commonly affecting the median nerve (carpal tunnel 
syndrome), is perhaps the most common discrete neurologic abnormality in adult 
hypothyroidism [9]. Less common is a sensory or sensorimotor neuropathy, for 
which evidence implicates both segmental demyelination and axonal degeneration 
[26]
. Deposition of acid mucopolysaccharides in the nerve and surrounding tissues 
leads compression of median nerve [8]. 
DIFFUSE PERIPHERAL NEUROPATHY: 
The peripheral neuropathy is usually relatively mild and predominantly sensory. 
The severity of the neuropathy appears to correlate with the duration of the disease 
rather than the severity of the biochemical abnormalities. Numbness and tingling of 
the extremities are frequent. The tendon reflexes are slow, especially during the 
relaxation phase, producing the characteristic “hung-up reflexes”; the phenomenon 
is due to a decrease in the rate of muscle contraction and relaxation rather than a 
delay in nerve conduction [15]. 
HYPOTHYROID MYOPATHY: 
 The major clinical features of hypothyroid myopathy include muscle pain, 
weakness, cramps, sluggish movements and reflexes, and myoedema (ridging of the 
muscle on percussion), increase in muscle bulk. Rhabdomyolysis and weakness of 
respiratory muscles are rarely reported [27]. 
 Kocher-Debre-Semelaigne syndrome is the unusual association of muscle 
hypertrophy in childhood hypothyroidism [28]. Stiffness and aching of muscles are 
common. Delayed muscle contraction and relaxation cause the slowness of 
movement and delayed tendon jerk. Myoclonus may be present [15].   
 EXAMINATION OF PATIENT: 
Physical examination: 
Examination of thyroid gland: The thyroid can be best palpated with both hands 
from behind the patient. Each lobe of the thyroid can be palpated by standing in 
front of the patient using the thumbs. In addition to the examination of the thyroid 
gland itself, the physical examination should include a search for signs of abnormal 
thyroid function and the extrathyroidal features of ophthalmopathy and 
dermatopathy. 
LABORATORY EVALUATION: 
Hormone assay: 
These tests are considered best and are widely used for the diagnosis of various 
thyroid disorders. An accurate estimation of thyroid hormones can be done by 
Radioimmunoassay (RIA) or by ELISA method. 
 Increased sensitivity and specificity of thyrotropin assays have greatly improved 
laboratory assessment of thyroid function. Because thyrotropin levels change 
dramatically in response to alterations of circulating Thyroxine or Triiodothyronine 
levels, a logical approach to thyroid testing is to first determine whether TSH is 
suppressed, normal or elevated. 
The finding of an abnormal TSH level must be followed by measurement of 
circulating thyroid hormone levels to confirm the diagnosis of hypothyroidism (in 
which thyrotropin elevated) or hyperthyroidism (Thyrotropin suppressed). 
Measurement of total T3, T4 and free T3, T4 are done to confirm the diagnosis of 
thyroid diseases.  
Normal values of thyroxine: [29] 
AGE 
MALES FEMALES 
SI unit nmol  µg/dl SI unit nmol µg/dl 
15-60 yrs 59-135 4.6-10.5 65-138 5.5-11 
>60yrs 65-138 5-10.7 65-138 5-10.7 
 
Normal values of Triiodothyronine: [29] 
AGE 
 
MALES 
 
FEMALES 
SI units ng/dl SI units ng/dl 
16-20yrs 1.23-3.23 80-120 1.23-3.23 80-120 
20-50yrs 1.08-4.14 70-204 1.08-4.14 70-204 
50-90yrs 0.62-2.79 40-181 0.62-2.79 40-181 
 
 
 
Normal values of thyrotropin: [29]  
AGE 
 
MALES 
 
FEMALES 
SI units SI units 
21wks-20yrs 0.7-64 0.7-64 
21-54yrs 0.4-4.2 0.4-4.2 
55-87yrs 0.5-8.9 0.5-8.9 
 
TEST TO DETERMINE THE ETIOLOGY OF THYROID DYSFUNCTION: 
Detection of antithyroid antibodies is useful in diagnosing autoimmune thyroid 
disorders. The presence of thyroid peroxidase (TPO) antibodies indicating the cause 
of hypothyroidism is autoimmune. On the other side, the absence of TPO antibodies 
requires a search for less common cause of hypothyroidism such as transient 
hypothyroidism, infiltrative thyroid disorders, and external irradiation.  
RADIOACTIVE IODINE UPTAKE: 
Measurement of radioactive iodine uptake (RAIU) is rarely needed in the evaluation 
of hypothyroidism. The RAIU may be normal or even increased when 
hypothyroidism results primarily from a biochemical defect in thyroid hormone 
synthesis rather than thyroid cell destruction leading to compensatory thyroid 
enlargement [15].  
 
THYROID SCAN: 
A radio nucleotide scan of thyroid using 123I, 125I, 131I or 99mTc is useful in 
demonstrating functioning thyroid tissue. On isotope scanning, swellings are 
classified into hot (overactive) or cold (underactive). About 80% of discrete 
swelling are cold, but only 15% prove to be malignant. 
FINE NEEDLE ASPIRATION CYTOLOGY:  
Fine needle aspiration cytology is the investigation of choice in discrete thyroid 
swellings. Thyroid disorders that may be diagnosed by FNAC include colloid 
nodules, thyroiditis, papillary carcinoma, medullary carcinoma, anaplastic 
carcinoma and lymphoma [30].  
ULTRASONOGRAPHY OF THYROID GLAND: 
Ultrasonography is a non invasive technique allows evaluation of an enlarged 
thyroid gland. It gives information about the shape and dimension of discrete 
nodules of thyroid gland.  
TEST FOR PERIPHERAL NEUROPATHY: 
Clinical examination: 
Physical examination of patients with suspected distal sensory, motor, or focal (i.e. 
entrapment or noncompressive) neuropathic symptoms should include assessments 
for peripheral neuropathy. 
Clinical investigation included a set of screening questions referring to the principal 
symptoms of polyneuropathy (i.e. muscle cramps, restless legs syndrome, burning 
feet, muscle pain, problems with object handling and “glove and stocking” 
Paresthesia) 
Testing for peripheral neuropathy begins with assessment of fine touch and pinprick 
sensation. Vibratory sense in the feet is tested with a 128-Hz tuning fork placed at 
the base of the great toe. Raffaello et al observed in their case reports of four 
hypothyroid patients, two of them had diminished touch, vibration and joint 
position sense [31]. 
Examination of deep tendon reflexes and muscle strength: With neuropathy, deep 
tendon reflexes are commonly hypoactive or absent. Ruurd F Duyff et al in their 
prospective study showed that 38% of the hypothyroid patients had weakness in one 
or more muscle groups and diminished ankle reflex [32]. 
Perform Tinel testing. Paresthesia and pain suggests median nerve injury. Perform 
cranial nerve testing. Have the patient walk on the heels and toes; heel-toe walking 
tests not only distal lower extremity strength but balance, as well. 
 
NERVE CONDUCTION STUDIES: 
The type and extent of nerve damage study can be analyzed using nerve conduction 
study. The parameters of motor nerve conduction study include the onset of latency, 
duration, and amplitude of compound muscle action potential (CMAP) and nerve 
conduction velocity. The sensory nerve conduction can be measured 
orthodromically or antidromically. As like that of motor nerve conduction study, the 
sensory nerve conduction measurement includes onset latency, amplitude, duration 
of sensory nerve action potential (SNAP) and nerve conduction velocity. 
The nerve conduction studies gives information about the involvement of axon, 
myelin, or both. 
ELECTROMYOGRAPHY: (EMG) 
Electromyography refers to recording of action potentials of muscle fibres firing 
singly or in groups near the needle electrode in a muscle. EMG changes help in 
objectively documenting the topography of disease process, such as focal versus 
generalized myopathy; or the neurogenic changes being restricted to nerve, plexus, 
root or segmental distribution; and duration of disease process, i.e. acute, subacute, 
and chronic.  
ELECTROMYOGRAHY FINDINGS IN HYPOTHYROIDISM: 
Electromyography reveals typical myopathic pattern with decreased amplitude and 
duration of motor unit potential as well as increase in polyphasia. Fasiculations, 
fibrillations, and sharp waves are uncommon in hypothyroid myopathy.  
 Nerve conduction studies and electromyography studies have an important role in 
the detection of peripheral neuropathy [33]. 
 
 
MUSCLE BIOPSY: 
In hypothyroid myopathy, the muscle biopsy changes of type II muscle fiber 
atrophy usually parallel the degree of clinical wasting and weakness. Type I fiber 
hypertrophy has been described particularly in women. Isolated necrotic fibres are 
rarely seen in this condition. In severely affected muscles, intracellular glycogen 
deposits may be found in muscle fibers and there may be vacuoles as well. Non 
specific ultrastructure features include myofibrillar degeneration, Z – disc 
streaming, lipofuscin accumulation, and mitochondrial alterations. The weakness in 
hypothyroidism is due to a complex set of effects of thyroid hormone deficiency on 
skeletal muscle structure and function. Impaired muscle energy metabolism appears 
to be the primary factor. Hormone replacement therapy improves most of the 
muscular abnormalities. 
NERVE CONDUCTION STUDY IN HYPOTHYROIDISM: 
Findings on nerve conduction studies depend on the pattern of nerve damage. Khedr 
et al in their electrophysiological study in hypothyroid patients showed that 52% of 
patients had peripheral nervous system affection. 35% of patients had entrapment 
neuropathy followed by diffuse distal axonal neuropathy (9%) and myopathy (9%) 
[8]
. 
 
Ettore Beghi et al conducted a nerve conduction study in hypothyroid patients, and 
found higher motor distal latencies with prolonged motor nerve conduction 
velocities for median, ulnar, sural, common peroneal nerves [34]. 
D.J. Dick et al performed nerve conduction studies in hypothyroid patients before 
and after the treatment with thyroxine and observed slowing of motor and sensory 
nerve conduction velocities and prolongation of distal latencies in median, ulnar, 
common peroneal, posterior tibial and sural nerve before treatment with thyroxine 
and reported all the nerve conduction velocities and latencies are returned to normal 
on treatment with thyroxine [35]. 
Yeasmin S et al has evaluated sensory neuropathy in hypothyroid patients. They 
found significantly prolonged sensory distal latencies with lower sensory nerve 
conduction velocities of median, ulnar, and sural nerve in their nerve conduction 
study and suggested that the thyroid hormones stimulate the mitochondrial 
respiratory activity to produce energy in form of ATP during aerobiosis under 
normal physiological condition. Hormones also increase the ATPase activity and 
consequently Na+/K+ pump activity cause subsequent alteration of pump dependent 
axonal transport and thereby may lead to peripheral neuropathy [36]. 
Fariba Eslamian et al has evaluated the electrophysiological changes in patients 
with overt hypothyroidism and their results are increases in median compound 
motor action potentials and sensory nerve action potentials (SNAPs) latencies and 
slowing of conduction as well as reduction in sural SNAPs amplitude. They 
reported 32.5% of carpal tunnel syndrome, 15% of neuropathy, and 7.5% of 
myopathy in patients with hypothyroidism [37]. 
 
INVESTIGATION FOR CENTRAL NERVOUS SYSTEM INVOLVEMENT 
IN HYPOTHYROIDISM: 
MRI: Magnetic resonance imaging is non-invasive and uses magnetic fields and 
radio waves instead of ionizing radiation. Structural MRI methods allow creating 
images of anatomical structures in an excellent spatial resolution. Magnetization 
transfer is sensitive to myelin content and is therefore useful in detecting early 
demyelination process. 
fMRI: Functional magnetic resonance imaging has become the tool of choice to 
study functional aspects of the human brain. fMRI in patients with thyroid disease 
of different duration and severity could help to identify functional aberrations such 
as memory impairments or altered emotional processing, which has long been 
suggested from animal studies. 
PET (positron emission tomography) & SPECT (single photon emission computer 
tomography): Thyroid hormones are known to affect the vascular system. 
Hypothyroidism is associated with impaired fibrinolysis and blood coagulation 
resulting in cerebrovascular disease. It also compromises protective endothelial and 
thrombocyte functions as well as lipid metabolism. 
PET & SPECT measurement of cerebral blood flow in hypothyroidism was 
associated with global, diffuse hypoperfusion. Several studies pointed to more 
regional effects including perfusion deficits pronounced in posterior brain region or 
in the parietal lobe [38]. 
 
ELECTROENCEPHALOGRAPHY: (EEG) 
Electroencephalography is a non-invasive technique in which the brain’s electrical 
activity is recorded from the scalp to evaluate the function of the brain. 
An excess of low voltage slow activity has been reported in hypothyroid adult 
patients. The alpha blocking response may be poor or even absent [39]. The EEG is 
diffusely abnormal in Hashimoto’s thyroiditis [26]. 
ELECTROPHYSIOLOGICAL STUDY IN HYPOTHYROIDISM: 
Clinical electrophysiological examination and evaluation consist of the recording, 
analysis, and interpretation of biochemical activity of muscles and nerve in response 
to volitional activation or electrical stimulation. 
Evoked potentials are voltage changes monitored from the electrically excitable 
tissue if the cerebral cortex, brainstem, and spinal cord in response to various 
applied sensory stimuli. The function of pathways leading to three different central 
nervous system sensory areas, the somatosensory cortex, the visual cortex, and the 
auditory region of the brainstem, can be evaluated using electro physiologic test [40]. 
Evoked potentials are frequently used to evaluate central nervous system 
physiology. Both electroencephalography (EEG) and evoked potentials (EPs) are 
used to measure the brain electrical activity. The EEG displays spontaneous brain 
activity as a continuous graph of voltage and frequency changes occurring over 
time. In contrast, EPs reflect activity of the central nervous system in response to 
specific stimuli [41]. 
Evoked potential recordings are useful in evaluating lesions in the afferent pathways 
under study. They assess the functional integrity of these pathways, whereas 
imaging techniques such as MRI and CT are useful in evaluating structural lesions 
of the brain. Thus, evoked potential studies sometimes reveal abnormalities missed 
by magnetic resonance imaging and vice versa. In patients with known CNS 
pathology, evoked potentials studies help to detect and localize lesions and also 
detect structural abnormalities in a variety of disorders [42]. 
VISUAL EVOKED POTENTIALS: 
Visual evoked potentials are electrical potentials differences recorded from the 
vertex in response to visual stimuli .The VEPs represent the mass response of the 
cortical and possibly sub cortical areas. Normal cortical responses are obtained only 
if the entire visual system is intact and disturbances anywhere in the visual system 
can produce abnormal VEPs, therefore the localizing value of VEP is limited [33]. 
VEP is a gross electrical response recorded from visual cortex in response to a 
changing visual stimulus such as multiple flashes (flash visual evoked potential) or 
check board pattern (pattern onset / reversal VEP). It can detect functional loss in 
the visual pathway from retina to the visual cortex. The visual stimulus may be 
unstructured, as in a flashing light, or structured, as in some form of pattern to the 
flash stimulus or the stimulus may be patterned, as in checkerboard presented on a 
video display unit. The essential feature is that while the pattern changes, the overall 
illumination remain the same. Black squares go white and white become black 
alternatively, the rate of the lightening of the dark squares being the same as that of 
the darkening of the light squares [43]. 
FLASH VER: 
This is a most crude test and it indicates that light has been perceived. It is a fovea 
dominated response and is relatively unaffected by opacities in the cornea and the 
lens.  It is therefore a useful test to grossly assess the intactness of the macula or the 
optic nerve. 
PATTERN REVERSAL VER: 
This depends on form sense and may give a rough estimate of visual acuity. It is 
more of fovea specific response. The timing of responses is more reliable than the 
amplitude [44]. The preferred stimulus for visual evoked potential testing is a 
checkerboard pattern of black and white squares. 
NORMAL VEP FINDINGS: 
The VEPs consist of a series of wave forms of opposite polarity. The negative 
waves are denoted by N and positive waves by P, which is followed by the 
approximate latency in ms. The commonly seen wave forms are N75, P100, and 
N145. The peak latency and peak to peak amplitudes of these waves are measured 
[45]
. 
BASIS OF VEP ABNORMALITIES: 
The VEP abnormalities may be latency prolongation, amplitude reduction and 
combined latency and amplitude abnormalities. The commonest cause of prolonged 
P100 latency is demyelination in the optic pathways where the amplitude of P100 
remains normal.  
CLINICAL USES OF VEP: 
The VEP study is a sensitive method for detecting the abnormalities in visual 
pathways especially anterior to the optic chiasma. It should be regarded as 
complementary to clinical examination and neuro-opthalmological investigations 
[33]
. 
BRAIN STEM AUDITORY EVOKED POTENTIAL: 
Brainstem auditory evoked potentials (BAEPs) are the potentials recorded from the 
ear and the scalp in response to a brief auditory stimulation to assess the conduction 
through the auditory pathway up to midbrain. The evoked potentials that appear 
following transduction of the acoustic stimulus by the ear cells create an electrical 
signal that is carried through the auditory pathway to the brain stem and from there 
to the cerebral cortex [45]. BAEPs comprise five or more waves within 10ms of the 
stimulus [33]. It may describe in terms of duration of onset of response [46]. 
BAEPs are useful to study in means of objectively and noninvasively the function 
of the auditory system, specifically the cochlea-auditory nerve-brainstem pathway, 
resulted in an extensive development of scalp recording of both near and far field 
potentials [39]. 
 
 
Early Auditory Evoked Potentials: 
Early auditory evoked potentials (early AEPs) have also been reported to as short –
latency auditory evoked potentials and corresponding to the responses recorded 
within the first 12msec after an auditory stimulus. 
Middle-Latency Auditory Evoked Potentials: 
Middle –latency auditory evoked potentials (MLPs) are potentials occurring 
between 12 and 50msec after acoustic stimulation. They can be recorded from 
transient or from high frequency stimuli.  
Middle latency auditory evoked potentials has been clinically applied in the 
assessment of hearing threshold in infants and children, the identification of 
dysfunction in central auditory pathways, and the evaluation of the central auditory 
pathways in candidates for cochlear implants.  
Late Auditory Evoked Potentials: 
Evoked potentials occurring 50msec or more after acoustic stimulation are called 
slow or late auditory EPs. These potentials can be subdivided into exogenous 
components N1, P1 and P2, which are primarily dependent on characteristics of the 
external stimulus, and endogenous components such as P300, N400, CNV, and the 
mismatch negativity, which are more dependent on internal cognitive processes [39]. 
Normal BAEP Findings: 
The BAEP consists of five or more distinct wave forms recorded within 10 ms of 
auditory stimulus and are generated in different regions of the peripheral and central 
auditory pathways. Wave I originates from the peripheral portion of auditory 
adjacent to cochlea. Wave II originates from cochlear nucleus, Wave III from 
superior olivary nucleus, wave IV from lateral meniscus, and wave V from inferior 
colliculi [33]. The absolute latency, inter peak latencies and amplitude of wave forms 
of BAEPs were measured. 
Interpretation of BAEPs: 
BAEP interpretation requires identification and measurement of waves I, III, and V 
and the measurement of I-V and I-III inter peak intervals. These values should then 
be compared with the normal values for the patient’s age and sex. First, absence of 
wave I with normal wave V probably reflects technical problems in recording. 
Second, absence of wave III is significant only when wave V is also missing or 
delayed. Third, BAEPs cannot be interpreted without considering the patients 
hearing status; conductive hearing loss and cochlear pathology may profoundly 
affect BAEP wave late latency and amplitude. 
Utilization of Latency-Intensity functions permits differentiation of four types 
of pathologies: 
1. Latency-intensity functions indicating conductive hearing loss. The functions 
are characterised by prolonged wave I and wave V with latency- intensity 
curves parallel to the normal curve. The I-V and I-III intervals are normal. 
2.  Latency-intensity functions indicating cochlear hearing loss. This type of 
abnormality accompanies high-frequency hearing loss of cochlear origin. It 
is characterised by a recruiting curve for wave I; that is, normal or mildly 
prolonged wave I latencies with loud clicks and greater delays with 
decreased intensity, resulting in a steep curve. Wave V is not drastically 
affected, and its curve is less steep, resulting in a shortened I-V interval. 
3. Latency-intensity functions indicating retrocochlear deficit type I. Wave I is 
prolonged with a steep latency-intensity function; Wave V is prolonged; 
therefore the I-V interval is prolonged. This type of abnormality has been 
reported in lesions affecting the eight nerves. 
4. Latency-intensity functions indicating retro cochlear deficit type II. The 
wave I latency-intensity curve is normal. Wave V and the I-V inter peak 
interval are prolonged. The latency-intensity function of wave V and the I-V 
interval is variable. A delayed wave V with normal wave I latency signifies 
that the delay has occurred somewhere after wave I (that is, central to the 
auditory nerve).A variation of this type of abnormal BAEP is characterised 
by normal wave I and absence of succeeding wave [39]. 
BAEP findings may be abnormal at a time when imaging studies show no definitive 
abnormality [42]. 
CLINICAL APPLICATION: 
1. BAEPs are effective in evaluating the integrity of the peripheral and    
central auditory pathways [39]. 
2. BAEPs have been used to detect subclinical brain stem pathology [42]. 
3. To assess the hearing in uncooperative patients and very young children.  
4. To detect the degree of hearing loss in infants [45]. 
SOMATOSENSORY EVOKED POTENTIAL: 
Somatosensory evoked potentials are the potentials generated by large diameter 
fibres (sensory fibres) in response to a sensory stimulus applied to them anywhere 
in their course, either in the peripheral or in the central portion of the pathway [45]. It 
depends on functional integrity of the fast-conducting large diameter group IA 
muscle afferent fibres and group II cutaneous afferent fibres and on the posterior 
column of the cord, although some fibres may follow a different, extralemniscal 
pathway [42]. 
The potentials recorded have different latencies and are accordingly called short, 
intermediate and long latency potentials. 
Somatosensory evoked potentials are generally elicited by electrical stimulation of 
median and posterior tibial nerves. 
Normal SEP Findings: 
SEP components are defined by latency and polarity. 
Components of median nerve SSEP: 
The components of median nerve SSEP recording that are important to clinical 
interpretation include: 
Erb’s point potential - recorded as the afferent volley transverses the brachial 
plexus. 
N13 - representing post synaptic activity in the central gray matter of the cervical 
cord. 
P14- arising in the lower brainstem, most likely in the caudal medial lemniscus. 
N18- representing post synaptic potentials generated in the rostral brain stem. 
N20- representing activation of the primary cortical Somatosensory receiving area. 
Normal Median SEP: 
Erb as potential is described as N9, which is seen as a principle negative peak in the 
EP1-EPc channel. Spinal potential (N11) is a negative peak, which is recorded at 
spinous process of fifth cervical vertebra referred to EPc. The subsequent negative 
wave is higher in amplitude and is designated as N13.Children between 1 and 4 
years normally have a prominent N11. The P14 potential is a positive peak widely 
distributed over the scalp and best recorded from Cc-EPc (Scalp – non cephalic 
Channel). In some normal individual, it may be of low amplitude and inconspicuous 
in all recording channels. It usually occurs 1ms after N13. The N18 is a negative 
peak broadly distributed over the scalp, beginning before N20, and usually apparent 
in non cephalic recording .i.e., Cc-EPc channel. The N20 is seen as a negative wave 
form in Cc-Fz and Cc-EP channels, and is usually identified as portion of negative 
potentials, just preceding the sharp drop off towards the succeeding cortical positive 
peak P25. In succeeding 40ms a series of cortical potentials are recorded which 
include N35, P45 and N60. 
The following parameters are measured for the analysis of median SEP: 
1. Latency 
2. Amplitude 
3. Inter peak Latency. 
The N9 latency is measured in EP1-EPc channel from stimulus artefact to its peak 
and amplitude from the peak to the succeeding positive deflection. The N13 latency 
measured at the C5Sp-EPc channel from the stimulus artefact to the peak. The 
amplitude is measured from peak of N13 to the next deflection. The latency of N20 
is measured to the point of maximum negativity just preceding the steep drop of 
P25 trough in Cc-fz channel. There are two important inter peak latencies (IPL), 
which are of clinical significance. 
1. Brachial plexus to Spinal cord (N9-N13). 
2.
 Central Sensory Conduction Time (N13-N20) [33]. 
MEASUREMENT OF THE CENTRAL CONDUCTION TIME (CCT): 
One of the advantages of SEP recording in clinical routine is to permit an evaluation 
of the transit time of the ascending volley in the central segments of the 
somatosensory pathways. 
Upper limb SEPs: 
Various montages and procedures have been proposed for measuring the CCT 
depending on weather the aim is merely to detect a conduction slowing and to 
follow up CCT values during the evolution of a disease in the same individual, or to 
locate accurately the site where conduction velocity is slowed down. In all types of 
montages the conduction in the proximal segment of brachial plexus roots can be 
evaluated by measuring the interval between the peaks of the supraclavicular N9 (or 
far-field P9) and the spinalN13 potentials. Techniques that provide the investigator 
with an index of global CCT abnormality  are considered to yield enough 
information  in many clinical situations; among these, the measurement of the 
interpeak between the cervical N13 and the parietal N20 components is the most 
widely used. 
The global CCT can be evaluated by measuring the intervals either between peaks 
of N13 and N20 potentials (peak CCT) or between the onset of N11 and N13 
potentials (onset CCT) [47]. 
FINDINGS OF EVOKED POTENTIALS IN HYPOTHYROIDISM: 
Ladenson et al conducted a study of visual evoked potentials in hypothyroid 
patients and found prolongation of P100 latency (P<0.05) following 12 to 24 weeks 
of long term oral L-thyroxine treatment. The mean P100 latency was significantly 
reduced (P<0.001) and it was concluded that reversible alteration of this readily 
measurable parameter in hypothyroid patients reflects an effect of thyroid hormones 
on central nervous system function [9]. 
Khedr et al evaluated peripheral and central nervous system alteration in 
hypothyroidism. They found significant prolongation of P100 latency and decrease 
in the VEP amplitude and significant prolongation of absolute latencies and 
interpeak of the different waveforms of BAEPs in hypothyroid patients. In addition 
to that , cognitive functions were significantly impaired in hypothyroid patient as 
measured by Wechsler intelligence scale and P300 [7]. 
Mastalgia et al conducted VEP studied in hypothyroid patients before and after 
with thyroxine and found P100latency was initially at the upper limit of or above of 
the normal range in seven cases and reported P100 latency returned to normal in 
four cases after the treatment with thyroxine and suggested that there is a reversible 
abnormality of conduction in the visual pathway in hypothyroidism [48]. 
Avramides et al studied VEP in hypothyroid patients before and after the treatment 
with thyroxine and found prolongation of P100 latencies in 7 out of 15 hypothyroid 
patients before treatment with thyroxine and reported P100 latencies was returned to 
normal in 4 patients when euthyroidism was achieved [49].  
Salvi et al studied VEP in patients with TAO (thyroid associated ophthalmopathy) 
and observed prolongation of P100 latency in hypothyroid patient and showed that 
patient with TAO reveals asymptomatic optic nerve dysfunction in the absence of 
deterioration of visual acuity [50]. 
Ozkardes et al has evaluated the effects of acute hypothyroidism on brainstem 
auditory evoked potentials. They found significant prolongation of wave I is BAEP 
and explained low body temperature, diminished myelin production and alteration 
in cerebral metabolism may be the possible cause for this prolongation of wave I in 
BAEP [51]. 
A.R.D.thornton and S.J.Jarvis showed a statistically significant reduction in the 
amplitudes of waves III and V and significant increase in the I-V interpeak latencies 
in hypothyroid patients. The measured abnormalities in I-V interpeak latencies may 
be explained on the basis of patients low body temperature [10]. 
Karlos Thiago Pinherio Dos Santo et al has done audiological evaluation in 
patient with acquired hypothyroidism and observed prolongation of absolute latency 
of wave I and the transient evoked otoacoustic emission were not present in a higher 
number of patients with hypothyroidism (20%) [52]. 
Yi-Hung Chou  and Pen-Jung Wang was studied Auditory Brainstem evoked 
potentials in early treated congenital hypothyroidism and found  pattern I, which 
causes prolongation of absolute latency of wave I, III, and V in hypothyroid patients 
[53]
.
 
Ritter showed that hearing loss can be the most common otorhinolaryngological 
manifestation of congenital and acquired hypothyroidism and auditory symptoms 
may happen alone or in association with vertigo and tinnitus [54]. 
Abdullah Ozkardes has evaluated the central nervous system alterations in acute 
hypothyroidism by somatosensory evoked potentials before and after the treatment 
with L-thyroxine. They found significant prolongation of mean central conduction 
time in both median and tibial nerve stimulated SSEPs in hypothyroid patient and 
showed improvement in central conduction time abnormalities on treatment with 
thyroxine and suggested that low body temperature, diminished myelin production 
and alteration in cerebral metabolism during acute hypothyroidism maybe the 
possible cause for the prolongation of central conduction time [12]. 
Coot J. Bongers–Shokking et al has evaluated SSEP in neonates with primary 
congenital hypothyroidism and observed prolonged latencies and prolonged central 
conduction time after the stimulus of median nerve and suggested that lack of 
thyroid hormones result in reduced myelin, synapse and dendrite formation [11]. 
Ozata et al has evaluated central motor conduction in thyroid patients and found 
significant prolongation of central motor conduction time in 4 of 20 hypothyroid 
patients. Improvement of CMCT abnormalities was observed in 1 of 4 hypothyroid 
patients after they become euthyroid [55]. 
Lai et al conducted somatosensory evoked potentials and peripheral nerve 
conduction studies in patients with primary hypothyroidism before and after 
treatment with thyroxine and reported 11 patients had significant prolongation of 
latencies of N9, N13, and N20 and only three patients had prolonged central 
conduction time and they showed significant improvement in SSEP and Peripheral 
nerve conduction studies after thyroxine treatment [56]. 
TREATMENT OF HYPOTHYROIDISM: 
Clinical manifestation of Hypothyroidism is treated with Levothyroxine sodium 
(thyroxine). A primary advantage of levothyroxine therapy is that the peripheral 
deiodination mechanisms can continue to produce the amount of T3 required in 
tissues under the normal physiologic control [15]. 
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 MATERIALS AND METHODS 
This study was conducted in the Department of Physiology, Thanjavur Medical 
College & hospital, Thanjavur. Case control type of study was done. The study 
period extended between may 2011 to 2012. The patients were selected from 
medicine and surgery department. 
Out of 40 subjects, 7 males and 33 females with Hypothyroidism of age group (17-
64 years) were selected. Diagnosis of hypothyroidism was confirmed when the total 
thyroxine level was below 4µg/dl and the thyrotropin level was above 4.5mU/ml. A 
history was taken, and a complete medical examination and neurological 
examination were out for every patient. Out of 40 controls, 10 males, 30 females, of 
age group (17-64 years) were selected.  
Inclusion criteria: 
• Patients with biochemical evidence of hypothyroidism (Serum total 
thyroxine < 4µg/dl, TSH > 4.5mU/ml. 
Exclusion criteria: 
• Diabetes mellitus. 
• Neurological disorders. 
• Psychiatric illness. 
• Seizures. 
• Hypertension.  
• Eye diseases (severe myopia, cataract, glaucoma etc). 
• Collagen disease. 
• Renal impairment. 
• Drug abuse. 
The nature of study was explained to all the subjects. Informed written consent was 
obtained from all the participants. The experimental protocol was approved by the 
ethical committee. 
The thyroid profile was carried out using ELISA method. The following 
electrophysiological parameters are studied:  
• VEP (Visual Evoked Potential) 
• BAEP (Brain stem Auditory Evoked Potential)  
• SSEP (Somatosensory Evoked Potential) 
All these parameters are recorded using four channel digital polygraph. Digital intex 
colour monitor, 17’’model no: IT-173 SB. 
METHOD OF RECORDING VEP, BAEP, SSEP: 
Electrodes are positioned using 10-20 electrode placement system [58]. 
VISUAL EVOKED POTENTIAL: 
Pre test instructions: 
1. The subject was told about the procedure of the test and got informed 
consent. 
2. The subject is asked to avoid applying hair spray or oil after the last hair 
wash. 
3. If the subject uses optical lenses, glasses should be worn during the test. 
4. The subject is instructed not to use any miotics and mydriatics 12 hours 
before the test. 
5. Full ophthalmological examination was carried out to determine visual 
acuity, pupillary diameter and field of vision. 
6. The room should be quite and comfortable. 
RECORDING OF VEP: 
Instrument setting for VEP: 
 
 
 
 
 
 
 
 
 
Setting VEP 
Sweep 20msec 
Sensitivity 10µv 
Low cut 2Hz 
High cut 200Hz 
Pulse 1/sec 
Pulse 
width 
0.1msec 
notch Off 
Recordings 
100 average was recorded using 
Checker board pattern stimulus given 
 PROCEDURE: 
The pattern-shift visual evoked potential was measured separately for each eye by 
following steps. 
1. The skin is prepared by abrading and degreasing. 
2. The recording electrode is placed at OZ using electrode paste as per 10-20 
international system of EEG electrode placement. 
3. The reference is placed at FPz. 
4. The ground is placed at the vertex (i.e.) at Cz 
5. The procedure is conducted in dark room with subject sitting at a distance of 
a 1 meter from the VEP screen showing pattern reversal stimuli in check 
board pattern with reversal rate 2/sec, contrast 50-80%, check size 28-32 of 
arc and number of trails is 100. 
6. From the waveform obtained (Figure 2) P100 latency is marked. P 100 is a 
positive potential at about 100ms.  
 
 
 
 
 
 
 
 VEP SHOWING P100 LATENCY 
 
 
 
FIGURE 2 
 
BRAINSTEM AUDITORY EVOKED POTENTIAL: 
Pre test instruction: 
1. The subject was told about the procedure of the test and got informed 
consent. 
2. The subject is asked to avoid applying hair spray or oil after the last hair 
wash. 
3. Examination of external ear, Rinne’s test, and Weber’s test are carried out. 
4. Subject is made to fully relax. 
5. Mild hypnotics can be used to ensure relaxation. 
6. Room should be quite and comfortable. 
RECORING OF BAEP: 
Instrument setting for BAEP: 
 
 
 
 
 
 
  
 
 
 
 
 
Settings BAEP 
Sweep 5msec 
Sensitivity 10µv 
Low cut 100Hz 
High cut 10Hz 
pulse 11/sec 
Pulse width 0.1 msec 
notch On 
Decibels 60Db 
Recordings 100 average was recorded using 
Click sound as stimulus. 
Procedure: 
1. The skin is prepared by abrading and degreasing. 
2. The electrode placement is at 
Channel 1 =Cz-Ai (ipsilateral ear) 
Channel 2= Cz-Ac (contra lateral ear). 
Ground electrode is placed at 20%from the nasion Fz. 
3. Head phones are placed on the ears for delivery of the auditory stimulus. 
Clicks are delivered at the rate of 8-10/sec. Intensity to set at 60 db. 
About 100 average is taken. 
4. From the waveform (figure 3) obtained wave I and V is marked first. 
Wave I is the first major up going peak usually follow a small stimulus 
artefact. 
5. Wave V appears at approx 6ms and is often combined with wave IV in to a 
single complex waveform. Wave III is the major peak between wave I and V 
.Wave II is typically the first major upward deflection in the Cz –Az 
waveform as wave I is markedly attenuated or absent there. 
6. From the above waveform inter peak latency I-III, III-V and I-V is obtained. 
 
 
 
 
 BAEP SHOWING WAVEFORMS I TO V 
 
 
 
FIGURE 3 
 
SOMATOSENSORY EVOKED POTENTIAL OF MEDIAN NERVE: 
 Pre test instruction: 
1. The subject was told about the procedure of the test and got informed 
consent. 
2. The subject is asked to avoid applying hair spray or oil after the last hair 
wash. 
3. History obtained to rule out nerve injury and Median nerve examination 
carried out. 
4. The subject is made to fully relax in supine position with head supported (in 
order to relax neck muscles). 
5. Mild hypnotic can be used to ensure relaxation. 
6. The room should be quite and comfortable. 
RECORDING OF SSEP: 
Instrument setting for SSEP: 
Settings SSEP 
Sweep 5msec 
Sensitivity 10µv 
Low cut 30 Hz 
High cut 3KHz 
Pulse 2/sec 
Pulse width 0.1msec 
Notch Off 
Recordings 100 average was recorded using 5mAmp 
Current. 
 
Procedure: 
1. The skin is prepared by abrading and degreasing. 
2. The electrodes are placed as  
              
              
 
 
3. The recordings obtained from the subject in lying posture with neck relaxed, 
by stimulating the median nerve at the wrist. 
4. Number of trials 100, analysis time 40ms, keeping low filter at 1-3 HZ [33]. 
5. From the waveform (figure 4), the following are measured N9 latency is 
measured in EPi-EPc channel from stimulus artefact to its peak. 
N13 latency is measured in Ci-EPc or Cc-Fz channel. 
 N9 -Distal brachial plexus. 
 N13 -rostral cervical spinal cord 
 N20 -thalamo cortical radiations. 
 
Brachial plexus to spinal cord   = N19-N13 
Central sensory conduction time = N13-N20 
Cortical latency   = N20 
 
 
 
 
Channel 1 Cc-Fz 
Channel 2 Cc-EPc 
Channel 3 C5Sp-EPc 
Channel 4 EPi-EPc 
 SSEP WAVEFORM 
 
 
FIGURE 4 
Statistical method: 
 Electrophysiological parameters were analysed by using statistical package SPSS 
version 18 and statistical analysis was done by student‘t’ test. 
 
 Fig: 2 VEP RECORDING 
 
 
 
Fig 3: VEP WAVEFORM 
 
 
 
 Fig 4: RECORDING OF BAEP 
 
 
 
Fig 5: BAEP WAVEFORM 
 
 
 
 
  
Fig 6: SSEP WAVEFORM 
 
 
 
  
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 RESULTS 
Out of 80 subjects, 40 were hypothyroid patients forming the study group and 
remaining 40 were normal subjects forming control group. 
In this study hypothyroid patients who form the study group were in age group 17-
64 years, mean 39.64 and the subjects in control groups were in the age group 17-64 
years, mean 35.75. 
The mean values and their standard deviation for the control group and the study 
group of hypothyroids were tabulated. 
The two groups differ significantly in various electrophysiological parameters like 
VEP, BAEP, and SSEP. ’P’value was derived from data analysis by using statistical 
package SPSS version 18 and statistical analysis was done by student‘t’ test. The 
statistical significance was considered at p value < 0.05. 
 
 
 
 
 
 
 DESCRIPTIVE STATISTICS 
 
Table -1: serum levels of T3, T4, and TSH in hypothyroid patients 
Item  
Hypothyroid  (n=40) 
Min. Max. Mean S.D 
T3 (ng/dl) 0.04 1.60 0.3867 0.37450 
T4 (µg/dl) 0.68 3.97 2.3900 0.74477 
TSH (mIU/L) 5.02 32.00 9.5910 5.30216 
 
 
Table -2: serum levels of T3, T4, and TSH in control group 
 
 
 
 
 
Item  
Control (n=40) 
Min. Max. Mean S.D 
T3 (ng/dl) 0.34 5.60 1.1458 0.88295 
T4 (µg/dl) 5.32 24.00 9.0480 3.98983 
TSH (mIU/L) 0.50 4.30 2.0575 0.95195 
Table-3: Electrophysiological findings in hypothyroid patients (n=40) 
 
 
 
 
 
 
Parameters  
 
Min 
 
Max 
 
Mean 
 
Std. Deviation 
 
VEP 
P100 Latency (ms) 
 
 
91.50 
 
 
114.50 
 
 
103.66 
 
 
5.65 
 
BAEP 
I-III Latency (ms) 
 
III-V Latency (ms) 
 
I-V Latency (ms) 
 
 
1.575 
 
1.30 
 
3.875 
 
 
 
 
3.625 
 
3.20 
 
6.57 
 
 
 
2.58325 
 
2.32475 
 
4.89475 
 
 
0.548135 
 
0.49836 
 
0.64379 
 
SSEP ( Median Nerve) 
N20 (ms) 
 
N13 (ms) 
 
N9 (ms)  
 
CCT( N20-N13) 
(ms) 
 
 
20.25 
 
12.69 
 
7.75 
 
3.55 
 
 
28.935 
 
18.935 
 
11.75 
 
13.65 
 
 
 
 
24.3379 
 
15.18555 
 
9.8344 
 
8.72625 
 
 
2.09836 
 
1.469805 
 
1.01036 
 
2.175545 
Table-4: Electrophysiological findings in control group (n=40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters 
 
Min 
 
Max 
 
Mean 
 
Std. Deviation 
 
VEP 
P100 Latency(ms) 
 
 
84.75 
 
 
101.50 
 
 
95.69 
 
 
4.10 
 
BAEP 
I-III Latency(ms) 
 
III-V Latency(ms) 
 
I-V Latency(ms) 
 
 
1.275 
 
1.16 
 
3.115 
 
 
3.14 
 
2.81 
 
5.2 
 
 
2.172 
 
1.88 
 
4.02525 
 
 
0.47811 
 
0.40041 
 
0.461345 
 
 
SSEP ( Median Nerve) 
N20(ms) 
 
N13(ms) 
 
N9(ms) 
 
CCT( N20-N13) 
(ms) 
 
 
19.00 
 
11.87 
 
6.38 
 
5.45 
 
 
23.00 
 
15.94 
 
10.44 
 
9.7 
 
 
20.31885 
 
13.23 
 
8.973 
 
7.08125 
 
 
0.94169 
 
0.71382 
 
0.8824 
 
1.02103 
 
 
  
Table -5 
The table -5 shows that there is a significant difference between control group and 
hypothyroid group in T3, T4, TSH levels. The statistical test used in the above table 
was student‘t’ test. 
 
 
PARAMETERS 
 
HYPOTHYROID 
n =40 
 
CONTROLS   
n= 40 
 
 
P value 
  
(Mean ± SD) 
 
(Mean ± SD) 
 
 
TRIIODOTHYRONINE 
[T3] (ng/dl) 
 
0.3867±0.37450 
 
 
1.1458±0.88295 
 
 
 
 
0.001 
 
 
THYROXINE 
[T4] (µg/dl) 
 
 
2.3900 ± 0.74477 
 
 
 
 
9.0480±3.98983 
 
 
 
0.001 
 
 
THYROTROPIN 
[TSH](mUI/L) 
 
 
9.5910 ±5.30216 
 
 
 
 
 
2.0575±0.95195 
 
 
 
0.001 
 Table -6 
The table -6 shows that there is a significant difference between control and 
hypothyroid group in latency P100 VEP, latency and interpeak latencies of BAEP, 
latency N20, N13, N9 and Central conduction time. The statistical test is used in the 
above table was student‘t’ test.  
 
 
PARAMETERS 
 
HYPOTHYROID 
n =40 
 
CONTROLS  
 n= 40 
 
 
P value 
  
(Mean ± SD) 
 
(Mean ± SD) 
 
 
VEP 
P100 latency (ms) 
 
 
103.66 ± 5.65 
 
 
95.69 ± 4.10 
 
 
0.001 
 
BAEP 
I –III Latency (ms) 
III –VLatency(ms) 
I – V Latency (ms) 
 
 
2.58325 ± 0.54813 
2.32475± 0.49836 
4.89475 ±0.64379 
 
 
2.172 ± 0.4781 
1.88 ± 0.4004 
4.02525 ± 0.4613 
 
 
0.003 
0.001 
0.001 
 
SSEP(Median 
Nerve) 
N20 (ms) 
N13 (ms) 
N9 (ms) 
CCT 
(N20 - N13) (ms) 
 
 
 
24.34 ±2.0983 
15.1855 ± 1.4698 
9.8344 ± 1.0103 
 
8.72625 ± 2.17554 
 
 
 
20.3188 ± 0.9416 
13.23 ± 0.71382 
8.973± 0.8824 
 
7.08125 ±1.02103 
 
 
 
0.001 
0.001 
0.001 
 
0.001 
Triiodothyronine level in hypothyroid patients show mean value 0.3867±0.37450 
and in control group it is 1.1458±0.88295 with P value 0.001 showing the 
difference Significant. 
 
 
 
 
 
 
 
 
Figure 7: Show significant difference in Triiodothyronine level between control   
group and hypothyroid patients. 
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 Thyroxine level in hypothyroid patients show mean value 2.39±0.74477 and in 
 Control group it is 9.048±3.98983 with P value 0.001 showing the difference is  
Significant. 
 
 
 
 
 
 
 
  
Figure 8: Show significant difference in Thyroxine level between control   
group and hypothyroid patients. 
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Thyrotropin (TSH) levels in hypothyroid patients show mean value 9.5910±5.30216 
and in control group it is 2.0575 ±0.95195 with P value 0.001 showing the 
differences Significant. 
 
 
 
 
 
 
 
 
 
Figure 9: Show significant difference in TSH level between control   group and 
hypothyroid patients. 
 
 
 
 
Thyroid-stimulating hormone (TSH)
0
5
10
15
20
Control Hypothyroid
0.001 < 0.05
m
IU
/L
VEP P100 latency in hypothyroid patients show mean value 103.66±5.65 and in  
Control group it is 95.69±4.10 with P value 0.001 showing the difference is  
Significant. 
 
 
 
 
 
 
 
 
Figure 10: Comparison of VEP P100 latency between control group and 
hypothyroid patients. 
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BAEP I-III latency in hypothyroid patients showing value 2.58325±0.548135 and in 
the control group it is 2.172 ±0.47811 with P value 0.003 showing the difference is 
significant. 
BAEP III-V latency in hypothyroid patients show value 2.32475±0.49836 and in the 
control group it is 1.88±0.40041 with the P value 0.001 showing the difference is 
significant. 
 BAEP I-V latency in hypothyroid patients show value 4.89475±0.64379 and in the 
control group it is 4.02525±0.461345 with the P value 0.001 showing the difference 
is significant. 
 
 
 
 
 
 
 
Figure 11: Comparison of BAEP I-III, III-V, I-V interpeak latency between 
control group and hypothyroid patients. 
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SSEP (median) N20 latency in hypothyroid patients show value 24.3379±2.09836 
and in the control group it is20.31885±0.94169 with the P value 0.001 showing the 
difference is significant. 
SSEP (median) N13 latency in hypothyroid patients show value15.18555±1.469805 
and in the control group it is 13.23±0.71382 with the P value 0.001 showing the 
difference is significant. 
SSEP (median) N9 latency in hypothyroid patients show value9.8344±1.01036 and 
in the control group it is 8.973±0.8824 with the P value 0.001 showing the 
difference is significant. 
 
 
 
 
 
 
 
 
Figure 12: Comparison of Latency of N-20, N-13, and N-9 between control 
group and hypothyroid patients. 
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SSEP (median) Central Conduction Time (N20-N13) latency in hypothyroid 
patients Show value 8.72625±2.175545 and in the control group it is 
7.08125±1.02103 with the P value 0.001 showing the difference is significant. 
 
 
 
 
 
 
 
Figure 13: Comparison of central conduction time between control group and 
hypothyroid patients. 
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DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
In this study, the electrophysiological parameters are evaluated in patients with 
hypothyroidism. The results of the electrophysiological study were compared 
between 40 patients with hypothyroidism and 40 healthy euthyroid subjects. 
Hypothyroidism, particularly when subclinical, is the most common 
endocrinological disorders, with a prevalence ranging from 4 to 10% of the adult 
population. Hypothyroid states have a multiple effects on structure, perfusion, and 
function of the CNS [38]. 
Central nervous system dysfunction is an important consequence of thyroid 
hormone deficiency. Although the peripheral nervous system has been extensively 
studied in hypothyroid patients by a variety of techniques, quantitation of the 
central nervous system derangements has been less precise (Ladenson). However 
clinical observations and a wide range of neuro imaging, electrophysiological and 
neuropathologic investigations conducted in recent decades have confirmed a 
deleterious effect of hypothyroidism on the morphological and functions of the 
CNS. In a recent study, PET and SPECT measurement of cerebral blood flow in 
hypothyroidism was associated with global, diffuse hypoperfusion. 
 
However, early involvement of the CNS, unlike the symptoms of peripheral 
neuropathy is usually subclinical and can be detected only through 
neurophysiological investigations. Measurements of stimulus conduction within the 
CNS by means of evoked potentials allow sensitive and reliable detection of 
subclinical changes. 
In this study, P100 latency of VEP is prolonged in patients with hypothyroidism and 
was found to be statistically significant. 
This study  results are consistent with those of Khedr et al, Mastalgia et al, 
Ladenson et al, Salvi et al, Avramides et al, Ladenson et al showed significant 
prolongation of P100 latency of VEP in hypothyroid patients, and reported that 
P100 latency of VEP was returned to normal on treatment with L- thyroxin and 
suggested that thyroid hormones have been shown to affect myelin synthesis, which 
is an important factor in determining the speed of impulse transmission along 
complex polysynaptic pathways such as those mediating the visual evoked 
potential. The reversible alteration of this readily measurable parameter in the 
hypothyroid patients reflects an effect of thyroid hormones on Central Nervous 
System. 
In this study, prolongation in the latency of Brain Stem Auditory Evoked Potentials 
(BAEP) I-III, III-V and I-V was found in patients with hypothyroidism and was 
statistically significant. 
 
Hearing is one of the most sensitive functions controlled by thyroid hormone, and 
early onset hypothyroidism (or) iodine deficiencies is known causes of deafness in 
humans and rodent model species. The thyroid hormone is required for the timely 
co- ordination of the complex set of differentiation events in maturing cochlea. 
Several studies (10, 51- 54) show prolongation of latency and inter peak latency of 
BAEPs. 
Metin Ozata et al showed that low body temperature, diminished myelin production 
and alteration in cerebral metabolism during acute hypothyroidism may be the 
possible explanations for the prolongation of wave I latency of BAEP. 
Ritter in his study showed that the symptoms relating to auditory pathway in 
hypothyroidism may be due to hyper osteosis of the otic capsule or central nervous 
system damage. 
In this study, the latency of median SSEP N20, N13, N9 and central conduction 
time are prolonged in hypothyroid patients indicating delayed peripheral and central 
nerve conduction and was statistically significant.  
The results of the present study agreed with those of Abdullah Ozkardes et al, Coot 
J Bongers – Shocking et al. Adullah Ozkardes et al showed prolongation of latency 
of N20, N13, N9 and prolongation of central conduction time acute hypothyroidism 
and suggested that low body temperature, diminished myelin production and 
alteration in cerebral metabolism during acute hypothyroidism may be the possible 
explanations for the prolongation of central conduction time.  
The latency depends on an intact, myelinated nerve as myelin and saltatory 
conduction are essential for fast action potential propagation in normal subjects. 
Slowing of conduction velocity or propagation of latency usually implies defect in 
myelination. The prolongation of cortical wave latency P100, BAEP I-III, III-V, I-V 
interpeak latency, SSEP N20, N13, N9 latency and prolongation of central 
conduction time are more significant that, it suggests there is central nervous system 
involvement. 
The present study results signify that there is a definite neurological deficit in 
thyroid deficiency, which can involve the central nervous system at much earlier 
stage. 
In hypothyroidism mentation is slow and cerebrospinal fluid protein is elevated. 
They affect mitochondrial oxidative activity, synthesis, degradation of proteins and 
sensitivity of tissue to catecholamines and hence demyelination occurs due to 
oxidative damage to myelin membrane and oligodendroglial cells.  Thus the present 
study results from VEP, BAEP, and SSEP data indicated hypothyroidism affect 
myelination. 
Peripheral and central nervous system alterations in hypothyroidism have shown 
that CNS is more vulnerable to the effects of hypothyroidism than peripheral 
nervous system. Therefore electrophysiological studies were suggested to be 
performed in hypothyroid subjects early in course of thyroid deficiency in order to 
detect nervous system involvement.  
 
 
 
 
  
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
  
CONCLUSION 
The result of present study shows that there is involvement of Central Nervous 
System in hypothyroidism. The hypothyroid patients show prolongation of latency 
in electrophysiological studies.  
Electrophysiological parameters like P100 latency of VEP, latency and inter peak 
latencies of I-III, III-V, I-V of BAEP and peripheral and cortical latencies of SSEP 
of median nerve were evaluated. The observation shows prolongation of latencies 
suggestive of central nervous system involvement in hypothyroidism.   
This study suggests that periodic evaluation of hypothyroid patients to 
electrophysiological test will help in monitoring the progress of neuropathy and 
earlier detection of nervous system involvement to reduce the morbidity of 
hypothyroid patients. 
However further studies are required to evaluate the correlation between the 
electrophysiological parameters and thyrotropin (TSH) level and duration of disease 
so that preventive measures can be suggested to prevent the central nervous system 
involvement.  
 
 
  
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
BIBLIOGRAPHY 
 
1. Eugene J.Barrett. The thyroid gland. In: Walter F Boron, Emile L. Boulpaep, 
editor. Medical physiology .2nd edition. Philadelphia: Saunders 
Elsevier;2009.p.1055 
2. Paul A FitzGerald, Endocrine disorder. In: Stephen J Mcphee, Maxine A 
Papaddes, Michael W.Rabow, editor.Current Medical Diagnosis and 
Treatment. New York:Mc Graw Hill;2012.p.1077 
3. Wilmar M.Wiersing, Hypothyroidism and Myxedema coam.In: J Larry 
Jameson, Leslie J De Groot, editor. Endocrinology Adult and Paediatrics.6th 
edition.Philadelphia:Saunders Elsevier;2010.p.1607-1610. 
4. J  Larry Jameson, Anthony P.Weetman, Disorders of Thyroid gland. In: J 
Larry Jameson, editor. Harrisons Endocrinology. 2nd edition. New York: Mc 
Graw Hill; p.62-74. 
5.  Joanne F Rovet, Thomas P. Foley, Jr, and Meranda Nakhla, 
Hypothyroidism. In:Fredric E.Wondisford,Sally Radovick,editor.Clinical 
Management of Thyroid Disease. Philadelphia: Saunders Elseivers; 
2009.p.123-124. 
6. Y.Anjana,O.p.Tandon, N.Vaney, S.V.Madhu.Cognitive Status in 
Hypothyroid Female Patients: Event- Related Evoked Potential Study 
Neuroendocrinology 2008 feb;88:59-66 
7. Eman M.Khedr, Lobna F.El Toony, Mohamed N.Tarkhan, Gamal Abdella. 
Peripheral and Central Nervous System Alterations in Hypothyroidism: 
Electrophysiological Findings. Neuropsychobiology 2000;41:88-94 
8. Steven C.Boyages. The Neuromuscular System and Brain in 
Hypothyroidism. Lewis E. Braverman, Robert D.Utiger. Introduction to 
hypothyroidism. In: Lewis E.Braverman, Robert D.Utiger, editor.Werner and 
Ingbar’s The Thyroid.8th edition.Philadelphia: Lippincort Williams and 
Wilkins; 2000.p.803-807. 
9. Ladenson PW, Stakes JW, Ridgway EC. Reversible alteration of the visual 
evoked potential in hypothyroidism. The American journal of medicine 
1984; Dec 77 (6): 1010-1014. 
10.  A.R.D. Thornton, S.J. Jarvis. Auditory brainstem response findings in 
hypothyroid and hyperthyroid disease. Clinical Neurophysiology 2008; 119: 
786-790. 
11. Coot J. Bongers-Schokking, Ernst J. Colon, Richard A. Hoogland, Cornelis 
J. De Groot, J. Leo Van Den Brande. Somatosensory Evoked Potentials in 
Neonates with Primary Congenital Hypothyroidism during the first week of 
therapy. Pediatric Research 1991; Jan 30 (1): 34-39. 
12.  Abdullah Ozkardes, Metin Ozata, Zeynel Beyhan, Ahmet Corakci, Okay 
Vural, Muzaffer Yardim et al. Acute Hypothyroidism leads to reversible 
alterations in central nervous system as revealed by 
Somatosensory evoked potentials. Electroencephalography and clinical 
Neurophysiology 1996; Jun 100 (5): 500-504. 
13.  Mario De Felice, Robert Di Lauro. Anatomy and Development of the 
thyroid. In: J Larry Jameson, Leslie J De Groot, editor. Endocrinology Adult 
and Pediatric. 6th edition. Vol II. Philadelphia: Saunders Elsevier 
2010.p.1342-1345. 
14.  Geoffrey J. Beckett , Anthony D. Toft. Thyroid dysfunction. In: William J. 
Marshall, Stephen K. Bangert, editor. Clinical Biochemistry: Metabolic and 
clinical aspects. 2nd edition. Philadelphia: Churchill Livingstone Elsevier 
2008. p.394. 
15.  Gregory A. Brent, P. Reed Larsen, Terry F. Davis. Hypothyroidism and 
Thyroiditis. In: Henry K. Kronenberg, Shlomo Melmed, Kenneth S. 
Polonsky, P. Reed Larsen, editor. William Textbook of Endocrinology. 11th 
edition. Philadelphia: Saunders Elsevier 2008. p. 377-397. 
16. Glenn Matfin. Disorders of endocrine control of growth & metabolism. In: 
Carol Mattson Porth, Glenn Matfin, editor. Pathophysiology – Concepts of 
Altered Health states. 8th edition. Philadelphia: Lippincott/ Williams & 
Wilkins 2009. p. 1032-1035. 
17.  Lauralee Sherwood. The Peripheral endocrine glands. Human Physiology. 
4th edition.  USA: Brooks/Cole 2001. p. 669-671. 
18.  Susan P. Porterfield, Bruce A. White. The Thyroid gland. In: Susan P. 
Porterfield, Bruce A. White, editor. Endocrine physiology. 3rd edition. 
Philadelphia: Mosby Elsevier 2007. p. 151-153. 
19.  Bruce A. White. The Thyroid gland. In: Bruce M. Koeppen, Bruce A 
Stanton, editor. Berne & Levy Physiology. 6th edition. Philadelphia: Mosby 
Elsevier 2008. p. 732-736. 
20.  Matthew Kim and Paul Ladenson. Thyroid. In: Lee Goldman, Andrew I. 
Schaffer, editor. Goldman’s Cecil Medicine. 24th edition. Philadelphia: 
Saunders Elsevier 2012. p.1452. 
21. Paul W. Ladenson. Thyroid. In: David C. Dale, Daniel D Federman, editor. 
A publication of the American college of physician, ACP Medicine. 3rd 
edition. Vol. I. Newyork: WebMD 2007. p. 605-608. 
22.  Christine E. Burness, Pamela J. Shaw. Thyroid disease and the nervous 
system. In: Michael J. Aminoff, editor. Neurology and General Medicine. 4th 
edition. Philadelphia: Churchill Livingstone Elsevier 2008. p. 357-374. 
23. Leslie J. De Groot. Adult Hypothyroidism. In: Leslie J. De Groot, P. Reed 
Larsen, Georg Hennemann, editor. The Thyroid and its disease. 6th edition. 
New York: Churchill Livingstone 1996. p. 342-344. 
24. William L. Meyerhoff, Stephen L. Liston. Metabolic Hearing loss. In: 
Richard Zorab, editor. Otolaryngology. 3rd edition. Vol.I. Philadelphia: W.B. 
Saunder 1991. p. 1677-1678. 
25.  Flavia Magri, Michelangelo Buonocore, Antonio Oliviero, Mario Rotondi, 
Anna Gatti, Silvia Accornero et al. Intraepidermal nerve fiber density 
reduction as a marker of preclinical asymptomatic small fiber sensory 
neuropathy in hypothyroid patients. European Journal of Endocrinology 
2010; 163: 279-284. 
26.  Neurological disease. In: Walter G.Bradley, Robert B. Daroff, Gerald M. 
Fenichel, Joseph Jankovic, editor. Neurology in clinical practice. 5th edition, 
Vol II. Philadelphia: Butterworth Heinemann Elsevier 2008. p. 1064. 
27.  Anthony A. Amato. Endocrine Myopathies and Toxic Myopathies. In: 
William F. Brown, Charles F. Bolton, Michael J. Aminoff, editor. 
Neuromuscular Function and Disease. Vol II. Pennsylvania: W.B. Saunders 
2002. p. 1399-1401. 
28.  O.P.Ghai. Hypothyroidism. In: O.P. Ghai, Piyush Gupta, V.k. Paul, editor. 
Ghai Essential Pediatrics. 6th edition. New Delhi: 2004.p. 482-483. 
29.  William L. Roberts, Gwendolyn A. Mc Millin, Carl A. Burtis. Reference 
Information for the clinical laboratory. In: Carl A. Burtis, Edward R. 
Ashwood, David E. Bruns, editor. Tietz textbook of clinical chemistry and 
molecular diagnostics. 4th edition. New Delhi: Saunders Elsevier 2006. p. 
2297-2300. 
30.  Zygmunt H. Krukowski. The thyroid gland and the thyroglossal duct. In: 
R.C.G. Russell, Norman S. Williams, Christopher J.K. Bulstrode, editor. 
Bailey & love’s Short practice of surgery. 24th edition. London: Arnold 2004. 
p. 785-786. 
31.  Raffaello Nemni, Edo Bottacchi, Raffaella fazio, Angelo mamoli, Massimo 
corbo, Massimo camerlingo et al. Polyneuropathy in hypothyroidism: 
clinical, electrophysiology and morphological findings in four cases. Journal 
of neurology, neurosurgery & psychiatry1987; 50: 1454-1460. 
32.  Ruurd F Duyff, Joan Van den  Bosch, D Martin Laman, Bert- Jan potter van 
loon, Win H J P Linssen. Neuromuscular findings in thyroid dysfunction: a 
prospective clinical and electro diagnostic study. Journal of neurology, 
neurosurgery & psychiatry 2000; 68: 750-755. 
33.  UK Misra, J Kalita. Visual Evoked Potential, Brain Stem Auditory Evoked 
Potential, Somatosensory Evoked Potential. Clinical Neurophysiology. 
2ndedition. India: Elseivers. p.309-372. 
34.  Ettore Beghi, Maria L Delodovici, Graziella Boglium, Vittorio Crespi, 
Felice paleari, Pierluigi Gamba et al. Hypothyroidism and polyneuropathy. 
Journal of neurology, neurosurgery & psychiatry 1989; 52: 1420-1423. 
35.  D.J.Dick, M.A.Nogues, R.J.M.Lane, P.R.W.Fawcett. Polyneuropathy in 
occult hypothyroidism. Postgraduate Medical Journal 1983 Aug; 59: 518-
519. 
36.  Yeasmin S, Begum N, Begum S, Rahman SMH. Sensory neuropathy in 
Hypothyroidism: Electrophysiological and clinical findings. Journal of 
Bangladesh society physiology 2007 Dec; (2): 1-6. 
37.  Fariba Eslamian, Amir Bahrami, Naser Aghamohammadzadeh, Mitra 
Niafar, Yaghoub Salekzamani, Keyvan Behkamrad. Electro physiologic 
changes in patients with untreated primary hypothyroidism. Journal of 
clinical Neurophysiology 2011 Jun; 28(3): 323-328. 
38.  Maximilian Pilhatsch, Michael Marxen, Christine Winter, Michael N 
Smolka, Michael Bauer. Hypothyroidism and Mood disorders: Integrating 
novel insights from brain imaging techniques. Thyroid Research 2011 Aug; 
4(1): 1-7. 
39.  Ernst Niedermeyer. Metabolic central nervous system disorders. Gastone 
G.Celesia and Mitchell G.Brigell. Auditory Evoked Potentials. In: Ernst 
Niedermeyer, Fernando Lopes Da Silva, editor. Electroencephalography-
Basic principles, clinical applications, and related fields. 5th edition. USA: 
Lippincott Williams & Wilkins; 2005. p.447, 1045-1060. 
40.  Andrew J. Robinson, with case studies provided by Robert M. Kellogg. 
Clinical electro physiologic examination and evaluation: principles, 
procedures, and interpretation of finding. In: Andrew J. Robinson, Lynn 
Snyder-Mackler, editor. Clinical electrophysiology, Electrotherapy and 
Electro physiologic testing. 3rd edition. Philadelphia: Wolter Kluwer 
Lippincott Williams & Wilkins; 2008. p. 457-459. 
41.  Ronald G. Emerson, Thaddeus S, Walczak, and Timothy A. Pedley. 
Electroencephalography and Evoked Potentials. In: Lewis P. Rowland, 
editor. Merritt’s Neurology.11th edition. USA: Lippincott Williams & 
Wilkins; 2005. p. 79-87. 
42.  Michael J. Aminoff. Electrophysiology. In: Christopher G. Goetz, editor. 
Text book of Clinical Neurology. 3rd edition. Philadelphia: Saunders 
Elsevier; 2007. p. 477-490. 
43.  Parson. Assessment of visual function. In: Ramanjit sihota, Radhika 
Tandon, editor. Parson’s Diseases of the Eye. 19th edition. New Delhi: 
Butterworth-Heinemann; 2003. p. 107. 
44. Dr. R.D. Ravindran. Electrophysiology of the Retina and the visual pathway. 
In: Dr. G. Natchiar, editor. Neuro-ophthalamology – a manual of 
postgraduate, Aravind Eye Hospital. India: 2003. p. 43-44. 
45.  G K Pal, Pravati Pal. Brain stem evoked potential, visual evoked potential, 
Somatosensory evoked potential. In: G K Pal, Pravati Pal, editor. Text book 
of practical physiology. 3rd edition. Hyderabad: Universities press; 2010. p. 
289-309. 
46.  Sharmila V. Srireddy, Colleen E. Ryan and John K. Niparko. Evaluation of 
the patient with hearing loss. In: Lawrence R. Lustig, John K. Niparko, 
Lloyd B minor, David S Zee, editor. Clinical Neurotology. London: Martin 
Dunitz, Taylor & Francis Group; 2003. p. 70-75. 
47.  Francois Mauguiere. Somatosensory Evoked Potentials: Normal Responses, 
Abnormal Waveforms, and Clinical Applications in Neurological Diseases. 
In: Ernst Niedermeyer, Fernando Lopes Da Silva, editor. 
Electroencephalography-Basic principles, clinical applications, and related 
fields. 5th edition. USA: Lippincott Williams & Wilkins; 2005. p. 1086-1087. 
48.  F.L. Mastaglia, J.L. Black, D.W.K. Collins, D.H. Gutteridge, R.W.M. Yuen. 
Slowing of conduction in visual pathway in Hypothyroidism. The Lancet 
1978 Feb; 311 (8060): 387-388. 
49.  Avramides A, Papamargaritis K, Mavromatis I, Sadddic G, VyzantiadisA, 
Milonas I. Visual evoked potentials in hypothyroid and hyperthyroid patients 
before and after achievement of euthyroidism. Journal of Endocrinology 
Investigation 1992 Nov; 15(10): 749-753. 
50.  Mario salvi, Elio Spaggiari, Fabrizio Neri, Claudio Macaluso, Eliana 
Gardini, Francesco Ferrozzi et al. The study of visual evoked potentials in 
patients with thyroid associated ophthalmology identifies asymptomatic optic 
nerve involvement. Journal of clinical Endocrinology and metabolism 1997; 
82(4):1027-1030. 
51.  Metin Ozata, Abdullah Ozkardes, M. Ali Gundogan. Effects of acute 
hypothyroidism on brainstem auditory evoked potentials. Tr. Journal of 
medical sciences 1998; 28: 133-137. 
52.  Karlos Thiago Pinheiro dos santos, Norimar Hernandes Dias, Glaucia Maria 
Ferreira da silva mazeto, Lidia Raquel de carvalho, Renan Luis Lapate, 
Regina Helena Garcia martins. Audiologic evaluation in patients with 
acquired hypothyroidism. 
53.  Yi-Hung Chou, Pen-Jung Wang. Auditory brainstem evoked potentials in 
early treated congenital hypothyroidism. Journal of child neurology 2002 Jul; 
17(7): 510-514. 
54.  Ritter F N. The effects of hypothyroidism upon the ear nose and throat. A 
clinical & experimental study. Laryngoscope 1967 Aug; 77(8): 1427-1479. 
55.  Ozata M, Ozkardes A, Dolu H, Corakci A, Yardim M, Gundogan M A. 
Evaluation of central  motor conduction in hypothyroid and hyperthyroid 
patients. Journal of Endocrinology Investigation 1996; 19(10): 670-677. 
56.  Lai CL, Liu CK, Tai CT, Lin RT, Howng SL. A Study of central and 
peripheral nerve conduction in patients with primary hypothyroidism: The 
effects of thyroxine replacement. Kaoh siung journal of medical science 
1998; 14(5): 294-302. 
57.  Jain.A.K. Electrocephalogram. Visual evoked potential. Brainstem auditory 
evoked potential. Manual of practical physiology. 3rd edition. Himachal 
Pradesh: Arya publication; 2009. P. 277, 294-302. 
 
 
  
  
 
 
 
 
ANNEXURE 
 
 
 
 
 
 
 
 
 
 CONSENT FORM 
 
Dr. M.Jayanthi, post graduate student in the Department of physiology, 
Thanjavur Medical College, Thanjavur is doing a comparative study on 
electrophysiological parameters in hypothyroidism. The procedures have been 
explained to me clearly. I understand that there are no risks involved in the 
above procedure. I hereby give my consent to participate in this study. The 
data obtained here may be used for research and publication.   
 
 
Signature: 
 
Name: 
 
Place: 
 
 
 
PROFORMA 
 
EARLY DETECTION OF CNS INVOLVEMENT IN          
HYPOTHYROIDISM BY ELECTROPHYSIOLOGICAL STUDY 
 
PATIENT NAME:   
 
AGE:                                                     SEX: 
  
OCCUPATION:                                   ADDRESS: 
 
PRESENT HISTORY: 
 
PAST HISTORY: 
 [Known Diabetic/ hypertension/Seizure/Psychiatric/ neurological disorders  
    /visual/ auditory deficit]  
 
PERSONAL HISTORY: 
 
TREATMENT HISTORY: 
 
GENERAL EXAMINATION: 
Ht:                            Wt: 
Higher function / Anemia / Cyanosis / Clubbing / Icteric / Pedal edema / 
Lymphadenopathy. 
 
VITAL SIGNS: 
PR:                            RR:                            BP:                             TEMP: 
 
SYSEMIC EXAMINATION: 
 
Respiratory System: 
 
Cardiovascular System: 
 
Abdominal Examination: 
 
Central Nervous System Examination: 
• Examination of eye: 
 
• Examination of ear: 
 
 
GENERAL INVESTIGATION: 
  
URINE: Albumin /sugar 
 
Blood glucose: 
 
SPECIAL INVESTIGATION: 
 
T3:                         T4:                     TSH: 
 
                      PROFORMA 
EARLY DETECTION OF CNS INVOLVEMENT IN HYPOTHYROIDISM BY 
  ELECTROPHYSIOLOGICAL STUDY 
           
    
VEP 
     
           PARAMETERS P 100(ms) R-L(ms) AMPLITUDE(µv) DURATION 
OBTAINED RIGHT         
 
VALUE LEFT         
INFERENCE    
           
    
BAER 
     
WAVE 
I II III IV V VI 
I-III 
IPL 
III-V 
IPL I-V IPL LATENCY(ms) 
OBTAINED RIGHT                   
VALUE LEFT                   
INFERENCE   
           SSEP 
           
PARAMETERS 
MEDIAN NERVE 
LATENCY  (ms) AMPLITUDE(µV) 
 
N9 
N20-
N9 
N20-
P13 
P13-
N9 N9 P13 N20 
OBTAINED RIGHT               
 
VALUE LEFT               
 
INFERENCE    
           
           
 
 
 
 
ABBREVIATIONS USED IN THIS STUDY 
BAEP    : Brain stem auditory evoked potential. 
CCT       : Central conduction time. 
CMAP    : Compound muscle action potential. 
CNS        : Central nervous system. 
DIT         : Diiodotyrosine. 
EEE        : Electroencephalography. 
EPs         : Evoked potentials. 
FNAC    : Fine needle aspiration cytology. 
IPL        : Interpeak latency. 
MIT       : Monoiodotyrosine. 
MLPs    : Middle latency auditory evoked potentials. 
PET       : positron emission tomography. 
RAIU    : Radioactive iodine uptake. 
SPECT  : Single photon emission computer tomography. 
SSEP     : Somatosensory evoked potential. 
TRH      : Thyrotropin releasing hormone. 
TSH      :  Thyroid stimulating hormone / thyrotropin. 
T3         :  Triiodothyronine. 
T4         :  Thyroxine. 
VEP      :  Visual evoked potential. 
 
 
 
 
 ELECTROPHYSIOLOGICAL PARAMETERS AND THYROID PROFILE - CONTROL GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
s.no AGE/   
SEX 
T3 
ng/dl 
T4 
µg/dl 
TSH 
mIU/l 
VEP P100   
LATENCY ms         
BAEP LT (ms) BAEP RT (ms) SSEP LT (ms) SSEP RT (ms) 
LT RT I-III III-V I-V I-III III-V I-V 
N-
20 
N-
13 N9 CCT N20 N13 N9 CCT 
1 58/F 0.45 6 1.2 96 98.5 2.93 1.7 4.63 2.93 1.6 4.53 19.4 13.8 9.25 5.6 20.9 13.5 7.75 7.4 
2 23/F 0.56 8 0.8 86.5 88.5 1.95 2.62 4.57 1.7 1.6 3.3 19.1 13.3 9.25 5.8 20.5 13.3 9.25 7.2 
3 32/F 1.23 7.8 1.36 99.5 98.5 1.9 1.73 3.63 1.88 1.97 3.85 20.5 12.6 8 7.9 21.9 12.8 8.88 9.1 
4 58/F 0.87 5.6 1.97 99.5 93.5 2.12 1.95 3.03 1.79 2.04 3.48 20.4 12.4 8.75 8 19.4 13.6 9.38 5.8 
5 59/F 1.14 5.4 1.43 84.5 85 2.93 1.5 4.43 2.83 1.35 4.18 20 14.1 8.38 5.9 21.5 13.4 9.12 8.1 
6 23/M 1.56 6.2 1.3 97.5 95 2.26 2.04 4.03 1.65 1.82 3.47 19.3 13.5 8.38 5.8 19.3 13.4 8.62 5.9 
7 43/F 0.98 7.3 2.94 100 97.5 1.98 1.5 3.48 2.35 1.13 3.48 20.6 13.8 9.62 6.8 19.6 13.1 8.62 6.5 
8 34/F 0.68 8.5 1.49 98 101 2.22 2.28 4.5 1.62 1.58 3.2 20.5 12.3 8.88 8.2 19.9 12.3 8.12 7.6 
9 29/F 0.46 7.2 2.03 99 98.5 2.43 1.57 4 1.57 2.78 4.35 19.1 13 9.25 6.1 20.9 12.9 9.88 8 
10 32/F 0.96 6.4 3.6 91.5 96.5 1.95 2.13 4.08 1.94 2.16 4.1 19.3 12.8 7.38 6.5 19.3 11.8 8.62 7.5 
11 34/M 2.3 10.2 0.82 96 96 2.2 2.28 4.48 2.72 1.96 4.68 20 12.8 8.62 7.2 19.1 12.4 9.25 6.7 
12 33/M 1.18 5.32 2.55 91 89 1.78 2.07 3.85 1.65 1.87 3.52 20.4 12.9 9.5 7.5 19.4 13.1 9 6.3 
13 27/M 1.46 6.2 2.06 94 90 2.82 1.43 4.25 2.6 2.92 4.2 20.6 12.1 9.5 8.5 21.5 12.9 9.62 8.6 
14 36/F 2.1 11 2.07 99 101 1.45 2.35 3.8 2.98 1.75 4.73 20 13.3 9.75 6.7 19.8 13.6 8.38 6.2 
15 35/F 1.96 16 0.5 94.5 94.5 2.6 1.53 4.13 2.33 2.12 4.45 19.5 13.9 10.5 5.6 19.5 12.4 9 7.1 
16 44/F 0.87 12 2 101 100 1.96 1.54 3.5 2.7 1.67 4.37 19 13 9 6 20.8 13.5 9.62 7.3 
17 41/F 0.98 21 0.68 99 99.5 2.07 2.12 4.19 1.8 2.2 4 20.3 13.3 9 7 19.5 12.9 8.38 6.6 
18 28/F 0.44 24 0.56 93.5 94.5 2.17 2.7 4.87 2.65 1.79 4.44 19.5 13.8 9.12 5.7 20.8 13.8 8.75 7 
19 62/F 0.98 9.6 1.42 93.5 91.5 1.98 1.62 3.6 1.85 1.8 3.65 20 12.8 6.25 7.2 21.5 11.6 6.5 9.9 
20 30/F 1.02 12.6 1.93 97 98 2.5 1.62 4.12 2.7 1.83 4.53 20.4 13.4 9 7 19.1 13 9.5 6.1 
 ELECTROPHYSIOLOGICAL PARAMETERS AND THYROID PROFILE - CONTROL GROUP 
s.no AGE/   
SEX 
T3 
ng/dl 
T4 
µg/dl 
TSH 
mIU/l 
VEP P100   
LATENCY ms         
BAEP LT (ms) BAEP RT (ms) SSEP LT (ms) SSEP RT (ms) 
LT RT I-III III-V I-V I-III III-V I-V 
N-
20 
N-
13 N9 CCT N20 N13 N9 CCT 
21 22/F 1.16 7.23 2.16 96 97.5 3.28 2.14 5.42 3 1.98 4.98 20.1 13.1 9.5 7 20.6 13.3 9.88 7.3 
22 31/F 0.46 10.6 1.53 100 99.5 1.63 2.35 3.98 1.86 1.47 3.33 19.1 13 10 6.1 20.4 14.9 9 5.5 
23 45/M 0.9 12.6 1.6 99.5 96 1.64 2.48 4.12 2.03 1.18 3.21 19.9 13.3 9.12 6.6 19.1 13.8 9.38 5.3 
24 18/F 0.76 7.4 2.49 87 90.5 2.08 1.7 3.78 1.7 1.97 3.67 20.8 13.6 10.4 7.2 21.9 13.8 8.75 8.1 
25 33/F 1.02 12.4 2.43 98.5 100 1.85 1.68 3.53 1.57 2.13 3.7 21.6 13.1 9.62 8.5 21 13.9 9.12 7.1 
26 29/M 0.64 6.8 1.34 100 97.5 2.6 1.19 3.79 1.56 2.22 3.78 19.3 13.1 7.25 6.2 20.1 13.4 9.88 6.7 
27 36/M 0.58 10.6 2.8 102 96.5 2.08 2.42 4.5 2.18 2.1 4.28 20.5 13 9.12 7.5 20.1 13.4 9.88 6.7 
28 19/M 0.34 5.6 2.16 94 95.5 3.14 1.43 4 2.85 1.63 4.2 20 13.4 8.88 6.6 20 13 9 7 
29 19/F 0.48 9.8 0.58 94 95.5 2.55 1.45 4 2.23 1.29 3.52 19.5 13.1 7.12 6.4 19 13.5 9.62 5.5 
30 34/M 0.59 5.68 3.2 99.5 86.5 2.2 2 4.2 2.04 2.58 4.62 20.8 13.1 9.12 7.7 20 12.8 8.25 7.2 
31 36/F 0.4 6.8 2.06 96.5 97.5 2.05 2.5 4.02 2.15 2.05 3.6 20.5 12.5 9.75 8 21.8 12.3 9.12 9.5 
32 27/F 0.69 7.2 2.03 95.5 95.5 1.76 2.1 3.86 2.82 1.48 4.03 20.5 13.5 10 7 20.4 12.3 7.38 8.1 
33 48/F 0.87 5.8 3.45 92.5 85.5 1.88 1.77 3.65 2.02 1.95 3.97 20.8 13.4 9.12 7.4 20.4 12.9 8.5 7.5 
34 55/F 1.33 6.2 2.49 97 93.5 2.57 1.53 4.1 2.13 2.14 4.27 20.6 13.3 9 7.3 20.8 13 6.75 7.8 
35 44/F 1.6 9.8 2.35 96.5 96.5 1.62 1.66 3.28 2.3 1.62 3.92 20 13.5 9.62 6.5 20.3 13.6 9.62 6.7 
36 39/F 1.67 7.28 3.8 95 98 1.1 1.52 4.62 1.6 1.74 4.34 22 15.4 10.9 6.6 23.4 14.4 9.12 9 
37 17/F 2 9.6 2.19 99 94 2.92 1.5 4.42 2.2 1.3 3.5 20 13.3 9.5 6.7 19.9 13 7.62 6.9 
38 24/F 0.9 8.2 2.83 96 95.5 1.85 1.95 3.8 1.72 2.18 3.9 20.1 14 9.5 6.1 22.9 13.9 9.12 9 
39 64/F 5.6 8.6 3.8 96 91.5 2.62 1.3 3.92 1.45 2.2 3.65 19.5 13.8 7.88 5.7 21 12.3 8.62 8.7 
40 29/M 1.66 7.41 4.3 101 102 2.67 1.87 4.54 1.82 2.52 4.34 22.6 13.1 10.3 9.5 22.9 16.5 10 6.4 
 
 ELECTROPHYSIOLOGICAL PARAMETERS AND THYROID PROFILE - HYPOTHYROID PATIENTS 
s.no AGE/   
SEX 
T3 
ng/dl 
T4 
µg/dl 
TSH 
mIU/l 
VEP P100   
LATENCY ms         
BAEP LT (ms) BAEP RT (ms) SSEP LT (ms) SSEP RT (ms) 
LT RT I-III III-V I-V I-III III-V I-V 
N-
20 
N-
13 N9 CCT N20 N13 N9 CCT 
1 22/F 0.14 3.2 9.3 111 107 2.78 2.98 5.7 3.14 2.6 5.74 23.4 14.1 10 9.3 25.5 14.3 9.12 11.2 
2 50/F 0.12 2.4 10.2 104 104 2.12 1.95 4.07 2.79 3.28 5.07 27.9 15.3 10.4 12.6 26.4 16.1 9.75 10.3 
3 21/F 0.11 2 10.5 110 103 3.22 3.12 6.34 3.87 2.93 6.8 24.9 13.1 10.8 11.8 23.8 15 9.38 8.8 
4 26/F 0.18 2.3 6.5 107 107 3 3.04 6.04 3.55 1.62 5.17 23.5 16.8 9.5 6.7 23.8 15.6 9.38 8.2 
5 34/M 0.12 3.6 5.4 103 101 3.15 2.32 5.47 3.1 2.52 5.62 24.3 14.1 8 10.2 25.9 15.9 8.75 10 
6 30/F 0.08 1.2 8 104 103 2 2.47 4.47 2.8 2.58 5.38 27.9 17.9 10 10 25.8 15 9.75 10.8 
7 54/M 0.09 2.28 12 104 103 2.63 2.64 5.27 3.57 1.75 5.32 23.3 14.4 8.62 8.9 25.5 15 8.12 10.5 
8 25/F 0.48 2.5 5.8 103 100 2.75 2.5 5.25 3.1 2.55 5.65 24.1 16.6 10.9 7.5 25.9 16.5 8.75 9.4 
9 39/F 0.13 1.2 7.46 110 108 2.37 2.03 4.4 2.15 2.3 4.45 21.9 13.3 10 8.6 23.6 14.6 10.5 9 
10 45/F 0.67 2.6 5.42 114 112 3.12 1.33 4.45 2.92 1.68 4.6 24.5 16.1 10.4 8.4 27.3 14.8 9.12 12.5 
11 50/F 0.13 2.6 8 107 110 1.8 3.04 4.84 2.45 2.52 4.97 27.4 17.8 10.4 9.6 23.8 14.6 10 9.2 
12 55/F 0.09 0.68 6.4 93 90 2.58 3.1 5.68 3.9 1.85 5.75 23.8 14.5 9.38 9.3 24.1 13.8 10.4 10.3 
13 40/F 0.1 3.97 6.5 104 105 3.35 2.53 4.88 3.43 2.67 5.1 26.6 16.1 10 10.5 23.8 14 10.9 9.8 
14 42/F 0.22 3.62 5.02 97 96 3.07 1.87 4.94 1.73 2.6 4.33 23.6 15.5 10.8 8.1 24 13.5 11 10.5 
15 27/F 0.23 3.12 7.22 105 106 2.63 2 4.63 2.14 2.63 4.77 26.5 19.8 11.6 4.7 26.9 16.3 10.9 10.6 
16 45/F 0.19 2.11 6.51 111 108 2.57 2.23 4.8 2.81 1.85 4.66 24.9 14 10.6 10.9 23.1 14 10.9 9.1 
17 17/F 0.8 3.3 5.2 102 103 2.32 2.18 4.5 2.47 2.65 4.12 29.1 13.3 9.75 5.8 25.5 13.9 9 11.6 
18 32/F 0.82 3.2 5.56 107 109 3.3 2.3 5.6 3.05 2.55 5.6 26.6 16.1 9 10.5 28.8 16.8 10.8 12 
19 33/F 0.04 1.8 8.79 97 97 3.23 1.85 5.08 1.63 3.15 4.78 20.6 13.9 8.75 6.7 20.9 14.1 10.6 6.8 
20 50/f 0.2 2.2 19.4 97 97.5 2.38 1.88 4.26 3.04 2.86 5.9 25.5 17.4 11.1 8.1 23.6 14.8 9.12 8.8 
 
 ELECTROPHYSIOLOGICAL PARAMETERS AND THYROID PROFILE - HYPOTHYROID PATIENTS 
s.no AGE/   
SEX 
T3 
ng/dl 
T4 
µg/dl 
TSH 
mIU/l 
VEP P100   
LATENCY ms         
BAEP LT (ms) BAEP RT (ms) SSEP LT (ms) SSEP RT (ms) 
LT RT I-III III-V I-V I-III III-V I-V 
N-
20 
N-
13 N9 CCT N20 N13 N9 CCT 
21 64/M 0.14 1.2 14.2 94 94.5 2.3 1.75 4.05 2.07 1.98 4.05 25 17.8 11 7.2 28.5 13.8 11.1 4.7 
22 34/F 0.23 2 9.4 100 100 3.32 2.4 4.72 2.75 2.2 4.95 22.6 15.6 9.38 7 23.6 15.8 9.12 7.8 
23 43/F 0.3 3.6 5.5 110 116 1.96 2 4.96 2.03 1.27 4.3 21.4 15 9 6.4 20 12.4 9.38 7.6 
24 40/F 0.12 2.2 20.2 103 114 2.94 1.6 4.54 2.5 2.1 4.6 22.4 15.3 10.9 7.1 23.1 17 11.6 6.1 
25 49/F 0.24 3.1 7.8 97.5 98 2.06 1.92 4.98 2.28 3.2 5.48 23.5 15.5 9 8 24.9 14.5 10.1 10.4 
26 35/F 1.2 2.9 6.2 103 105 2.12 2.3 4.42 2.3 3 5.3 23.4 17.4 10 6 24.4 18.1 8.5 6.3 
27 18/F 1.6 2.8 6.8 108 103 1.7 2.4 4.1 2.33 1.5 3.83 25.9 14.8 9 9.1 21.4 15.9 10.9 5.5 
28 45/F 1.08 2.3 8.69 100 101 2.18 1.97 4.15 3.03 1.75 4.78 23.1 16.5 7.38 6.6 22.5 13.4 9.12 9.1 
29 50/F 0.98 2.43 6.82 102 102 2.32 2 6.32 2.98 3.09 6.07 23.4 19.5 11.4 3.9 26.9 16.4 10.5 10.5 
30 63/F 0.26 1.8 12.5 113 114 2.12 2.8 3.92 1.9 2.82 4.72 21.3 13.8 11.9 7.5 23.1 15.4 10.5 7.7 
31 64/F 0.16 1.62 10.2 104 107 2.08 2.8 4.88 2.25 3.12 5.37 20.5 13.8 8.88 6.7 20.1 14.8 11.6 5.3 
32 19/F 0.83 2.02 7.91 93 90.5 3.02 2.4 5.42 3.2 2.2 5.4 22.3 14.6 10.6 7.7 26.3 16.3 8.88 10 
33 47/F 0.64 2.2 20.2 102 104 2.32 2.2 4.52 1.87 2.28 4.15 23 15.3 10.5 7.7 24.8 16.3 9.62 8.5 
34 26/F 0.2 1.6 32 105 102 1.97 2.85 4.82 2.15 1.75 4.9 23.8 15.6 9 8.2 27.1 13.9 8.5 3.2 
35 42/F 0.94 2.42 7.2 101 101 2.1 2.92 4.02 2.1 2.38 4.48 28.9 14.1 9.88 14.8 21.6 16.8 10.5 4.8 
36 40/F 0.14 1.84 9.4 101 101 3.35 1.88 5.23 2.77 1.76 4.53 24.9 15.9 10.6 9 23.9 13.1 8.38 10.8 
37 50/M 0.56 1.89 11.2 104 102 2.25 1.7 3.95 2.82 1.4 4.22 24.5 15.6 8.12 8.9 24.3 14 8.38 10.3 
38 41/M 0.32 2.2 8.4 111 110 2.83 2.35 4.18 2.3 1.85 4.15 22.8 13 8 9.8 23 13.3 10.3 9.7 
39 45/M 0.43 3.2 7.2 111 107 1.93 2.27 4.2 1.45 2.2 4.65 23.8 14.3 9.62 9.5 25.3 14.6 9.25 10.7 
40 34/M 0.16 2.4 12.6 101 115 2.52 2.75 5.27 2.18 2.37 4.55 25.9 13.5 10.8 12.4 22.6 14.6 9.62 8 
 
